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ABSTRACT

Jayasundera, Keerthi B. Ph.D., Purdue University, December 2014, Metal-Protein
Interactions for Proteomics Applications. Major Professor: Weiguo A. Tao.

In the quest of deciphering biological mechanisms, the understanding of proteins
and their functions is a vital component. However the complexity of the proteome poses
an immense challenge for analytical chemists to explore it comprehensively. Currently
mass spectrometry is at the forefront of proteome analysis, providing great capabilities to
couple with modern separation techniques for wide applications. One major objective of
current proteomic technologies is to identify proteins of interest among high background,
in particular from complex biological samples. A variety of techniques have been
developed over the years to simplify protein samples, which are broadly classified as
enrichment, high abundance protein depletion and sample fractionation. Metal ions play
critical roles in most protein enzymes and their interactions with proteins have been well
documented, but their applications in proteomics are underdeveloped. We have been
developing and applying metal-protein interaction based approaches for proteomics
studies due to their affordability, versatility and tunability. Previously, the Tao lab
introduced Polymer-based Metal Affinity Capture with Ti(IV) (PolyMAC-Ti) for
phosphopeptide enrichment in solution phase as opposed to commonly used solid phase
extraction methods. In chapter 2 we discuss further extension of PolyMAC technology to

xiii
PolyMAC-Zr and the use of complementary metal ion enrichment to study Syk
dependent phosphorylation in B-cells. In chapter 3, we discuss a study to couple
PolyMAC-Ti with anti-phosphotyrosine antibody to investigate Syk and Lyn dependent
phosphorylation in B-cells. In chapter 4, we introduce a method to capture and fractionate
proteins based on copper-protein interactions. Its unique application in enriching and
fractionating secretomes was demonstrated by identifying low abundance cytokines and
chemokines.

1

CHAPTER 1: INTRODUCTION

The detection of any proteome in its entirety with current instrumentation is
hindered by the proteome complexity for several reasons: (i) constant flux in expression
pattern in response to internal and external stimuli (ii) diversity and heterogeneity
between different cell types of the same organism owing to alternate splicing of mRNA
and post translational control1 and (iii) the large dynamic range of protein abundances2.
For example, protein abundances in human cell and plasma proteomes span over 7 and 10
orders of magnitude respectively3 while the most sensitive mass spectrometric methods at
present can monitor only a dynamic range of 4-5 orders of magnitude4. The large
dynamic range of protein concentrations in biological samples poses a challenge for mass
spectrometrists to identify low abundance proteins such as biomarkers and therapeutic
targets in complex biological samples. Current solutions include the enrichment of
proteins of interest, depletion of high abundance proteins and sample fractionation5, 6.
Targeting specific classes of proteins of interest is usually achieved based on the
affinity between proteins and various other biological and chemical moieties5, 6.
Antibodies are used in all three of the aforementioned methods in proteomics. Antibodybased approaches are widely used to enrich proteins and peptides based on specific
consensus sequences7, 8, tyrosine phosphorylation9, 10, glycosylation11, acetylation12 and
ubiquitination13. Further, antibodies are used to deplete high abundant proteins to
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improve the proteome coverage particularly in serum samples 14, 15. Human serum is the
source of choice for biomarker and drug target discovery due to presence of secreted
proteins from tissues and organs in response to varying health conditions in our body as
well as the ease of collection. However, 22 proteins constitute 99% of the total plasma
protein mass, and serum albumin alone accounts for 50% of it3, 16, 17. Antibody-based
high abundance protein depletion kits are commercially available that are capable of
depleting up to 58 most abundant proteins18-20 depending on the extent of depletion
needed. Furthermore, immunoaffinity chromatography combines the use of liquid
chromatography with the specific binding of antibodies or related agents21. It is a
versatile, powerful purification method based on well-characterized antibody-target
interactions, making it amenable for use in many applications, including
immunoextraction22, immunodepletion23, chromatographic immunoassays24, and postcolumn immunodetection25 for clinical and diagnostic assays for drugs, toxins, and
biomarkers.
Although antibody based methods provide high specificity and tight binding
toward the analytes, producing high quality antibodies are time consuming and costly.
When complex biological samples are applied, non-specific interactions and antibody
inactivation by proteases are common problems. Further, some antibodies may leach
during the experimental procedures due to necessary harsh washing and elution
conditions. Therefore non-antibody methods have been developed to provide cost
effective and robust alternatives for sample simplification, enrichment, depletion and
fractionation. For example, metal – phosphate affinity and hydrazide chemistry are
commonly used as enrichment strategies prior to mass spectrometric analysis16, 17, 26in
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phosphoproteomics and glycoproteomics respectively. Moreover, ProteoMiner27, 28 is a
unique technology that uses a combinatorial hexapeptide library coupled beads in equal
quantities to achieve high abundant protein depletion and low abundant protein
enrichment in a single step. An equal number of molecules from each protein are retained
by the beads, leading to the depletion of high abundant proteins and enriching low
abundant proteins. However, this method can only be used to obtain qualitative
information because the enrichment technique disrupts the protein concentration profile.
Finally, two dimensional (2D) gel electrophoresis and a wide variety of chromatographic
techniques have been used to fractionate protein and peptide samples prior to mass
spectrometric analysis. Different types of chromatographic methods are available such as
reversed phase, ion exchange, size exclusion, or affinity to be selected for protein
separation5, 6, 29
In the quest of developing low cost, versatile proteomics approaches, metalprotein interaction based methods have gain immense effectiveness. The variety of
differential interactions possible between different metals and ligands on proteins provide
many avenues to explore this aspect. The metal-ligand interactions are classified based on
hard soft acid base theory (HSAB)30, 31 in which all the metal ions have acid properties
and ligands have base properties. Ca2+, Mg2+, Mn2+, Fe3+, Ti4+, Zr4+, Cr3+ and Co3+ ions
are categorized as hard acids and interact preferentially with hard bases such as H2O,
RCOOO- , PO43-, OH-, serine and threonine. Fe2+, Co2+, Ni2+, Cu2+ and Zn2+ ions are
categorized as intermediate acids and interact preferentially with intermediate bases such
as NO2-, N3-, pyridine and imidazole. Cu+, Ag+, Hg+, Pd+ and Pt+ ions are categorized as
soft acids and interact preferentially with soft bases such as RSH, RS-, methionine and
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cysteine30, 31. Moreover, various types of interactions have been identified between
proteins and metal ions such as, (i) indirect interaction via organic ligands, (ii) indirect
interaction with hydrophobic regions via inorganic ligand, (iii) supramolecular clatherate
compounds and (iv) coordination interactions with the functional groups of amino acid
residues30, 31. The interaction via organic ligands occurs through bridged complexes, for
example, iron-porphyrin units in hemoglobin and the metal-phosphate interaction. At
present, the metal-phosphate chemistry is the major enrichment strategy used in
phosphoproteomics. Heavy metal ions such as mercury and gold interact with
hydrophobic regions of protein molecules through inorganic ligands such as iodide. The
iron storage protein ferretin forms a supramolecular clatherate in which Fe3+ is
incorporated in the cavity formed by multiple ferretin units. The formation of
coordination bonds between the metals and amino acids play a significant role in the
structure and function of metal-protein systems. The possible coordination sites on
proteins are carboxylic groups, peptide bonds, amine groups, hydroxyl groups (serine,
threonine, and tyrosine), thiol groups (cysteine), and imidazole (histidine). The different
combinations of coordination sites, coordination structures, bond nature, and metal ions
create a wide variety of possibilities for metal-protein interactions30, 31. Therefore we
focused on further exploring the metal-protein interactions for proteomics applications
and in this thesis we present applications of Polymer-based Metal Affinity Capture
(PolyMAC) for phosphopeptide enrichment and Immobilized Metal Affinity
Chromatography for identification of low abundance proteins in complex mixtures.
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1.1 Phosphopeptide Enrichment
Many different approaches have been employed for phosphopeptide enrichment
to date and can be mainly categorized under affinity purification, chemical derivatization
and chromatographic separation techniques. As an example, phosphorylated peptides and
proteins can be affinity-purified by antibodies capable of recognizing specific regions or
phosphorylated residues. Such methods, however, have demonstrated useful applications
mostly in enrichment of tyrosine phosphorylated proteins and peptides32, 33. For more
global analyses, affinity-based methods using Immobilized Metal ion Affinity Capture
(IMAC) and Metal Oxide Affinity Capture (MOAC) exploit the formation of coordinate
bonds between the negatively charged phosphate group and the metal ions. Fe (III) 34, 35 ,
Ga (III) 36, Al(III) and Ca(II)37 have shown good affinity toward phosphate groups, and
Fe(III) has especially been extensively used in IMAC. More recently, a much more
specific set of Ti(IV)- and Zr(IV)-functionalized IMAC beads have also been introduced.
MOAC is based on the same basic principles as IMAC, where titanium dioxide 38, 39 and
zirconium dioxide 40, 41 have been successfully used for phosphopeptide capturing and
applied in numerous biological studies42, 43.
Another phosphopeptide capture approach is based on selective modification of a
phosphate group preceding enrichment and is known as chemical derivatization. This has
been achieved through beta-elimination of a phosphate group, followed by Michael
addition of a stable chemical group such as 1,2-ethanedithiol. These modified peptides
may subsequently be affinity-purified using a relatively simple capture step, such as
biotin-avidin interaction44, 45. Further, derivertization of phosphate to has been used to
covalently couple phosphopeptides on to a poly(amine) dendrimer in a single step46. This
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method has been successfully applied to identify and quantify phosphopeptides from
complex mixtures. In theory, this method improves the fragmentation efficiency during
MS/MS by avoiding neutral loss and increases the ionization efficiency by decreasing the
negative charge of phosphopeptides. However, the extensive sample loss and unavoidable
side reactions have limited the usefulness of chemical derivatization47.
Furthermore, chromatographic techniques such as strong cation exchange
(SCX)48, strong anion exchange (SAX)49 and hydrophilic interaction chromatography
(HILIC)50 have been applied directly for phosphopeptide enrichment. SCX and SAX
separate molecules based on the charge. The SCX stationary phase has negatively
charged functional groups that retain cations under acidic conditions so it is possible to
elute phosphopeptides in earlier fractions51-53, whereas SAX has reversed polarity and
separation properties. HILIC utilizes a hydrophilic stationary phase allowing the analyte
to interact through hydrogen bonding, which retains phosphorylated peptides longer on
the column50. Although the initial attempts were made to use SCX, SAX and HILIC
directly for phosphopeptide enrichment, the experimental data suggest that by themselves
they are not very practical due to low specificity. At present, such separation techniques
are essentially used to pre-fractionate peptides in large scale phosphoproteomics studies
in combination with more specific enrichment methods, such as IMAC and MOAC, to
simplify the sample complexity42, 43.
The current most popular enrichment approaches, IMAC and MOAC, chelate
phosphopeptides to an affinity group mounted on a solid support, resulting in
heterogeneous reaction conditions that can lead to poor binding site accessibility and low
reproducibility. As a solution, the Tao lab recently introduced Polymer-based Metal ion
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Affinity Capture (PolyMAC), a reagent based on a titanium (IV)-functionalized poly
amidoamine (PAMAM) dendrimer, which showed exceptionally high reproducibility and
selectivity 9. A dendrimer is a soluble, polymeric nano material with a globular protetinlike structure which provides easily modifiable surface functional groups. In chapter 2 we
discuss the development of PolyMAC-Zr, a novel zirconium (IV)-functionalized
PAMAM G4 dendrimer, capable of effective enrichment of a unique array of
phosphopeptides and the use of complementary phosphopeptide enrichment of
PolyMAC-Ti and PolyMAC-Zr to investigate Syk dependent phosphorylation in B cells.
In chapter 3 we present enrichment of tyrosine phosphorylated peptides using
phosphotyrosine antibody and PolyMAC-Ti in sequential to investigate Syk- and Lyndependent events in B cells.

1.2 Isolation of Low Concentration Proteins from Complex Matrices
Not only the proteome complexity, but also the complexity of the sample matrix
adds upon the difficulty of identification of low abundance proteins. Therefore, many
sample purification methods have been developed over the years to eliminate matrix
molecules such as lipids, metabolites and detergents. The earliest approaches utilized the
relative solubility of proteins in which the protein component was precipitated by
changing the properties of the solvent54. Some examples are, addition of salts, organic
solvents such as acetone, varying the pH or the temperature54, 55. However, incomplete
protein precipitation is a common problem in solubility based methods. More recently
Filter-Aided Sample Preparation (FASP)56 was introduced to purify protein samples from
complex matrices. In FASP, proteins are retained on a membrane while the low
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molecular weight components and detergents pass through the membrane. Thus retained
proteins are digested and eluted for further analysis. However, FASP suffers from lengthy
sample preparation times, sample loss and incomplete removal of detergents.
Protein sample purification and simplification can be achieved simultaneously
using 2D gel electrophoresis or chromatographic techniques. Since it was first
introduced57, 2D gel electrophoresis has evolved at different levels and become a
powerful technique for protein separation and the method of choice for differential
protein expression analysis. This technique has an excellent resolving power; it is
possible to visualize over 10,000 spots corresponding to over 1,000 proteins on a single
gel as well as multiple spots containing different molecular forms of the same protein58.
Nevertheless, it suffers from several major limitations related to reproducibility59, poor
representation of low abundant proteins60, proteins at the extremes of acidity, basicity,
size and hydrophobicity61, and difficulties in automation of gel-based techniques62.
Moreover, the co-immigration of multiple proteins in a single spot makes quantification
difficult.
Due to aforementioned limitations in gel electrophoresis, most recent
developmental efforts have been focused on chromatographic techniques. Proteins can be
separated based on physical properties including shape, charge and size, as well as
chemical properties such as isoelectric point (pI), hydrophobicity and affinity to various
ligands5. In chromatography protein fractionation is achieved by manipulating either the
mobile phase or the stationary phase5, 6, 29. Mobile phase properties can be altered by
changing the slope (time) of the gradient, buffer pH and salt concentration, as well as
using various additives5, 6, 29. Different types of stationary phases are available such as
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reversed phase (C4, C8 etc.), ion exchange (SCX), size exclusion, normal phase (silica),
or affinity (antibody, apatmer, biotin etc.) to be selected for protein separation5, 6, 29.
The basic principle of affinity chromatography is based on the ability of proteins
to bind selectively and reversibly to a complementary molecule attached to a solid
support5, 63. Thus, proteins that do not poses complementary binding sites for the affinity
ligands pass directly through the column or can be eluted easily in early fractions. The
bound proteins are then eluted in the reverse order of the strength of the interaction.
Although antibodies directed against specific proteins or a group of proteins remain the
most popular affinity method, there are numerous other methods that have been
developed over the years. These methods include lectin affinity for glycoproteins64-67,
immobilized metal affinity chromatography (IMAC) containing nickel for histidine
tagged protein68 and gallium for phosphoproteins36. While studying metal-protein
interaction with different metals immobilized on IMAC, we observed that Cu2+
demonstrated a unique ability to capture over 98% of the protein component of cell lysate
and serum samples. Furthermore, it was capable of successfully isolating secreted
proteins over FASP from the complex matrix. This suggested that copper – protein
interaction can be applied to capture proteins from complex mixtures and matrices and
subsequently fractionate to identify low abundant proteins. In chapter 4, we describe the
development of IMAC-Cu based protein fractionation method and its application to
identify low abundant proteins in secretome.
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CHAPTER 2: POLYMAC-Zr FOR PHOSPHOPEPTIDE ENRICHMENT

2.1 Introduction
B cells are a vital component of the adaptive immune system that recognize
foreign antigens through a cell surface immunoglobulin known as the B cell receptor
(BCR) for antigen1. B cell activation through BCR stimulation results in proliferation and
differentiation of B cells to form both antibody-producing and memory cells. Crosslinking the BCR by antigen engagement initiates phosphorylation of immunoreceptor
tyrosine-based activation motifs (ITAMs) by the Src-family kinase, Lyn and subsequent
recruitment of the tyrosine kinase, Syk. Multiple adaptor proteins and effector proteins
including the B-cell linker protein BLNK, the guanine nucleotide exchange factor Vav,
phospholipase C-

(PLC), and phosphatidylinositide 3-kinase (PI3K) associate to

form signaling complexes2 that trigger downstream pathways such as activation of Btk,
mobilization of Ca2+ 3 and activation of the Ras/MEK/ERK pathway. The interaction
between a phosphorylated ITAM and the SH2 domains of Syk, coupled with the
phosphorylation of the kinase on tyrosine, is essentially required for all BCR-mediated
signaling events.
The contribution of Syk to the adaptive immune response in B cells is well known
and characterized. However, studies have also identified a large number of diverse
biological functions for Syk, including cellular adhesion, phagocytosis, osteoclast
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maturation, platelet activation and vascular development2. The involvement of Syk in the
pathogenesis of allergy, autoimmune diseases, carcinoma and hematological
malignancies has made it an important therapeutic target2, 4-6. Thus, knowledge of the
downstream pathways that mediate the diverse functions of Syk are of considerable
interest. As Syk is a tyrosine kinase, most studies have focused on Syk-dependent
tyrosine phosphorylation,7 which is largely limited to immediate downstream signaling
events and direct substrates8. Since Syk functions upstream of multiple pathways of
which serine/threonine kinases (e.g., PKC, Erk, Akt, etc.) are major components, changes
in its activity would be expected to affect many downstream events regulated by protein
phosphorylations on serines and threonines. This study was designed to identify Sykdependent downstream pathways in activated B cells at the proteomics level, focusing
mainly on such serine and threonine phosphorylation events.
Mass spectrometry is the major tool for analyzing protein phosphorylation in a
high throughput manner. Phosphopeptide enrichment is a necessary prerequisite in
phosphoproteomics due to the low stoichiometry of protein phosphorylation and the low
abundance of phosphoproteins9, 10. Many different approaches have been employed for
phosphopeptide enrichment11, and can be categorized mainly under affinity purification10,
12-20

, chemical derivatization21, 22 and chromatographic separation23-25. The most popular

enrichment approaches, immobilized metal ion affinity chromatography (IMAC)13-16 and
metal oxide affinity chromatography (MOAC)17-20, chelate phosphopeptides to an affinity
group mounted on a solid support. This heterogeneous condition can lead to poor binding
accessibility and low reproducibility. Recently we introduced Polymer-based Metal ion
Affinity Capture (PolyMAC), a soluble reagent based on a titanium (IV)-functionalized
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PAMAM dendrimer, which demonstrated enhanced reproducibility and selectivity26.
Other studies have shown the effectiveness of using both Zr- and Ti-based reagents for
phosphopeptide enrichment, as well as the ability of each to capture a unique set of
phosphopeptides27. Therefore, to complement our titanium-bound nanopolymer, we
developed PolyMAC-Zr, a zirconium (IV)-functionalized PAMAM G4 dendrimer. Here,
we present PolyMAC-Zr as a novel reagent for phosphopeptide enrichment and utilize
the complementary PolyMAC-Ti and PolyMAC-Zr enrichment methods to examine the
role of Syk-dependent phosphorylation in BCR signaling. Quantitative
phosphoproteomics based on Stable Isotope Labeling via Amino Acid in Culture
(SILAC)28 was employed to identify downstream effectors of Syk. Using the Syk
substrate-site inhibitor piceatannol7 and comprehensive sample fractionation with reverse
phase liquid chromatography (RPLC) or hydrophilic interaction chromatography
(HILIC), we were able to quantify close to 5,000 sites of phosphorylation that were
significantly affected by the activity of Syk after BCR stimulation from over 16,000
identified unique phosphorylation sites. Functional and pathway annotations confirmed
many known functions of Syk, but also revealed potential novel roles including a role in
modulating changes in protein ubiquitination.
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2. 2 Methods

2.2.1 Synthesis of PolyMAC-Zr Reagent
Polyamidoamine dendrimer generation 4 (PAMAM G4) solution (200 µl;
provided as 10% wt/vol in methanol; Sigma-Aldrich) was dried in a microcentrifuge tube
and redissolved in 1 ml of dimethyl sulfoxide. Then 6 mg of Boc-aminooxy acetic acid,
15 mg of N-Hydroxybenzotriazole (HOBt) and 10 µl of N,N'-Diisopropylcarbodiimide
(DIC) were dissolved in 1 ml of DMSO in a microcentrifuge tube and reacted for 30 min
at room temperature with shaking. The above two solutions were transferred into a 10 ml
round-bottom flask and stirred overnight at room temperature. Then 3 ml of water was
added to the reaction mixture and dialyzed against water to remove excess reagents and
concentrated using a 3500 molecular weight cut-off centrifugal filter. The mixture was
transferred to a 10 ml round-bottom flask and an equal volume of 250 mM MES (2-(Nmorpholino) ethyanesulfonic acid; pH 5.5) buffer was added to it. Next 16 mg of
carboxyethyl phosphonic acid, 16 mg of N-hydroxysuccinimide and 160 mg EDC (1ethyl-3-(3-dimethylaminopropyl)carbidiimide hydrochloride) were added to the mixture
and stirred overnight at room temperature. The solution was dialyzed against water and
one-third of it was reacted with 0.1 M solution of ZrOCl2 for 1 1/2 hours at room
temperature. The mixture was dialyzed against water and transferred to a glass tube and
evaporated to complete dryness. Then the solid was redissolved in 80% trifluoroacetic
acid, reacted for 1 1/2 hours and evaporated under N2 gas. The mixture was dialyzed
successively in 1:4 DMSO: water mixture and water. The final PolyMAC-Zr product was
stored at 4 oC.
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2.2.2 Isolation of Phosphopeptides from DG75 Cell Lysates
DG-75 cell culture was grown to 80% confluency in RPMI-1640 media (Gibco)
substituted with 10% inactivated FBS, 1% sodium pyruvate, 0.5% treptomycin/penicillin,
and 0.05% β-mercaptoethanol. Then the cells were washed with PBS, collected, and
frozen at -80 °C. Cells were lysed in 1 mL of lysis solution (50 mM Tris-HCl, pH 7.5,
150 mM NaCl, 1% NP-40, 1 mM sodium orthovanadate, 1x phosphatase inhibitor
cocktail (Sigma-Aldrich), 10 mM sodium fluoride) for 20 minutes on ice. The resulting
mixture was centrifuged at 16,100 × g for 10 minutes, and supernatant containing soluble
proteins was collected. The protein concentration was measured using the BCA assay.
DG-75 protein lysate was denatured and reduced in 50 mM trimethyl ammounium
bicarbonate containing 0.1% RapiGest and 5 mM dithiothreitol for 30 minutes at 50 °C.
The proteins were further alkylated in 15 mM iodoacetamide for 1 hour in the dark at
room temperature, and digested with proteomics grade trypsin at 1:100 ratio overnight at
37 °C. The pH was adjusted below 3 with hydrochloric acid and the sample was
incubated for 40 minutes at 37 °C. The sample was centrifuged at 16,100 × g and
supernatant collected. The resulting peptides were desalted with a Sep-Pak C18 column.
The enrichment of phosphopeptides was carried out using 100 µg samples, according to
the protocol described below.

2.2.3 Phosphopeptide Enrichment
The peptide mixture was dissolved in 100 µl of the loading buffer (200 mM
glycolic acid, 1% trifluoroacetic acid and 50% acetonitrile), 5 nmol of PolyMAC-Zr was
added to it and incubated for 10 minutes at room temperature. Then 250 µl of capture
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buffer (300 mM HEPES buffer at pH 7.7) was added to increase the pH above 6.3 and
transferred to a spin column (Boca Scientific) containing 50 µl of Carbolink coupling
agarose gel (Thermo Scientific). The samples were incubated with beads for 10 minutes
and centrifuged at 2,300 x g for 30 seconds to remove the flowthrough. The gel was
washed with 200 µl portions of loading buffer, twice with washing buffer (100 mM acetic
acid, 1% trifluoro acetic acid, 80% acetonitrile) and once with water. Then the
phosphopeptides were eluted off the gel-bound PolyMAC-Zr by incubating twice with
100 µl portions of 400 mM ammonium hydroxide solution. During washing and elution,
each incubation step was carried out for 5 minutes with shaking. PolyMAC-Ti
enrichment was carried out in a similar fashion, as described before26.

2.2.4 Growing DG75 Cell Lysates in SILAC “Heavy” and “Light” Media
For SILAC experiments, cells were grown to 50% confluency in SILAC RPMI1640 media (Gibco) substituted with 10% dialized inactivated FBS (Sigma-Aldrich), 1%
sodium pyruvate, 0.5% streptomycin/penicillin, 0.05% β-mercaptoethanol, and either LLysine and L-Arginine for “light” samples, or 13C6-Arginine and 13C6-Lysine (Isotec) for
“heavy” samples in 5% CO2 at 37ºC. Cells were grown for at least 6 divisions to ensure
complete incorporation of the “heavy” amino acids (confirmed by mass spectrometry
analysis; data not shown). Before each set of experiments, “light” and “heavy” cells were
normalized on both cellular and protein levels.
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2.2.5 Piceatannol Treatment and Igm Pathway Stimulation
The cell cultures were collected separately, washed with PBS and resuspended in
PBS to obtain a cell density of 2 x 107 cells per milliliter, followed by treatment with
piceatannol at the concentration of 50 µg per milliliter. Then the cells were incubated at
37oC for 30 minutes. The B cell receptor signaling pathway was stimulated by treating
the cells with the anti-IgM antibody at a concentration of 10 µL per milliliter and
incubated at 4oC for 15 minutes. Finally, the cells were washed with PBS, collected, and
frozen at -80 °C.

2.2.6 Sample Fractionation and Phosphopeptide Enrichment
Cells were lysed, protein content extracted, and the concentration was determined
using the BCA assay as described above. Then, 2.5 mg samples of “heavy” and “light”
labeled protein preparations were normalized mixed and digested with trypsin. The
peptide sample was injected into Agilent 1100 HPLC system and separated either using
4.6 mm x 150 mm XBridge BEH C18, 3.5 µm particle Reverse Phase Liquid
Chromatography (RPLC) column (Waters) or 4.6 mm x 200 mm Polyhydroxyethyl A,
5µm particle Hydrophilic Interaction Chromatography (HILIC) column (PolyLC Inc.).
For the HILIC fractionation, the 5 mg peptide sample was dissolved in 2 ml of solvent B
(0.1% formic acid in acetonitrile) and the sample was injected in 90% solvent B at a flow
rate of 0.1 mL/min. Solvent A consisted of 0.1% formic acid in water. After loading the
sample onto the column, it was washed with 90% solvent B for 15 minutes at 0.5 ml/min
flow rate. Peptides were eluted in 85% B to 65% B gradient in 40 minutes followed by
65% B to 20% B gradient in 20 minutes at the same flow rate. For the RPLC
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fractionation, the 5 mg peptide sample was dissolved in 4 mL of solvent A (10mM
TMAB in water, pH 8) and the sample was injected in 98% solvent A at a flow rate of 0.5
ml/min. After loading the sample onto the column, it was washed with 98% solvent A for
10 minutes at 1 ml/min flow rate. Peptides were eluted over 98% A to 60% A gradient in
60 minutes at 0.5 ml/min flow rate (solvent B used for elution was 10mM TMAB in
acetonitrile, pH 8). For each separation, twenty fractions were collected. For the two sets
of RPLC fractions, phosphopeptide enrichment was carried out with PolyMAC-Zr and
PolyMAC-Ti, whereas the phosphopeptides in HILIC fractions were enriched only with
PolyMAC-Zr.

2.2.7 LTQ-Orbitrap Analysis
Peptide samples were redissolved in 10 µl of 0.25% formic acid and injected into
the Eksigent nano LC Ultra 2D system. The reverse phase C18 was performed using an
in-house C-18 capillary column packed with 5 µm C18 Magic bead resin (Michrom; 75
µm i.d. and 12 cm of bed length). The mobile phase buffer consisted of 0.1% formic acid
in ultra-pure water with the elution buffer of 0.1% formic acid in 100% CH3CN run over
a shallow linear gradient (from 2% CH3CN to 35% CH3CN) over 90 min with a flow rate
of 300 nl/min. The electrospray ionization emitter tip was generated on the packed
column with a laser puller (Model P-2000, Sutter Instrument Co.). The Eksigent Ultra 2D
HPLC system was coupled with a hybrid linear ion trap Orbitrap mass spectrometer
(LTQ-Orbitrap Velos; Thermo Fisher). The mass spectrometer was operated in the datadependent mode in which a full scan MS (from m/z 300 – 1700 with the resolution of
30,000 at m/z 400) was followed by 20 MS/MS scans (for SILAC samples - 7 MS/MS

22
scans were used) of the most abundant ions. Ions with charge state of +1 or undetermined
charge states were excluded. The mass exclusion time was 90 s.

2.2.8 Database Search
The LTQ-Orbitrap raw files were searched directly against human database using
SEQUEST or MASCOT on Proteome Discoverer (Version 1.3, Thermo Fisher).
Proteome Discoverer created DTA files from raw data files with minimum ion threshold
15 and absolute intensity threshold 50. Peptide precursor mass tolerance was set to 10
ppm, and MS/MS tolerance was set to 0.8 Da. Search criteria included a static
modification of cysteine residues of +57.0214 Da and a variable modification of
+15.9949 Da to include potential oxidation of methionine and a modification of +79.996
Da on serine, threonine or tyrosine for the identification of phosphorylation. Searches
were performed with full tryptic digestion and allowed a maximum of two missed
cleavages on the peptides analyzed from the sequence database. False discovery rates
(FDR) were set to 1% for each analysis. Proteome discoverer generates a reverse “decoy”
database from the same protein database and any peptide passing the initial filtering
parameters that were derived from the decoy database is defined as false positive
identification. The minimum cross-correlation factor (Xcorr) filter was readjusted for
each individual charge state separately in order to optimally meet predominant target
FDR of 1% based on the number of random false-positive matches from the reverse
“decoy” database. Thus, each dataset had its own passing parameters. The number of
unique phosphopeptides and non-phosphopeptides identified were then counted using inhouse software and compared. Phosphorylation site localization from CID spectra was
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determined by PhosphoRS on Proteome Discoverer 1.3. For SILAC experiments, in
addition to the above parameters, a dynamic modification of +6.020 Da was added on
arginine and lysine. The quantification method was set to SILAC 2plex (Arg6, Lys6) and
Light/Heavy ratios were reported.

2.2.9 Data Analysis
A list of all phosphopeptides identified in different fractions was prepared and
unique peptides were extracted based on the m/z value and the charge state using inhouse software. The phosphosite localizations were obtained from PhosphoRS
assignments. If the same peptide sequence appears more than once in this list with
different light/heavy ratios, the average ratio was calculated and assigned for that
particular sequence. The mean and the standard deviation were calculated for the nonphosphorylated peptides and the cut off values for phosphopeptides were determined by
considering the 2x the standard deviation from this mean. In order to predict upstream
kinases for identified phosphosites, an in-house software utilizing the kinase motifs listed
on human protein reference database was used.

2.2.10 Pathway Analysis
A list of proteins corresponding to peptides showing significantly increased or
decreased phosphorylation was extracted. This list with decreased and increased
phosphorylation and the corresponding SILAC ratios were submitted to Ingenuity
Pathway Analysis (IPA) (Ingenuity Systems). The IPA criteria were set to include only
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known human cellular proteins and their direct interactions. In addition, protein functions
were predicted using DAVID bioinformatics tool.

2.2.11 Cell Culture and Biological Reagents for Ubiquitination Study
DT40 B cell lines were grown to a density of 0.4 x 106 cells/mL in RPMI-1640
medium containing 7.5% FBS, 1% chicken serum, 100 U/mL penicillin, 100 mg/mL
streptomycin and 50µM 2-ME. For cell stimulation, phorbol 12-myristate-13-acetate
(PMA) was used (Sigma-Aldrich). For immunoblotting, anti-Syk (N-19) and antiubiquitin (P4D1) were purchased from Santa Cruz Biotechnology. Anti-GAPDH was
purchased from Ambion.

2.2.12 Ubiquitination Assay
DG75 cells in RPMI 1640 media were treated with 5 µM MG132 for 3 hours in
an incubator at 37oC, washed and resuspended in PBS. The cells were divided into four
groups; two were treated with piceatannol at a concentration of 50 µg/mL and the other
two were treated with DMSO control by incubating in a 37 oC water bath for 30 minutes.
One set from each treatment group was stimulated with anti-IgM antibody for 15 minutes
on ice. Cells were washed with PBS and pellets were prepared. Cell pellets were lysed
using a solution containing 1% Noindent P-40, 50mM Tris-Cl pH 8.0, 100mM NaCl,
5mM EDTA, 1mM NaVO3, 10mM NaF, 1x phosphatase inhibitor cocktail (SigmaAldrich), and 1x mammalian protease inhibitor cocktail (Sigma-Aldrich). Proteins were
separated using SDS-PAGE and protein ubiquitination was measured via Western blot.
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Flag-tagged ubiquitin was over-expressed in Syk-EGFP-expressing or Syknegative DT40 chicken B cells. Cells were then treated with 100ng/mL PMA or DMSO
for the indicated times. Cells were lysed using a solution containing 1% Noindent P-40,
50mM Tris-Cl pH 8.0, 100mM NaCl, 5mM EDTA, 1mM NaVO3, 10mM NaF, 20 mM
N-ethylmaleimide, 1x phosphatase inhibitor cocktail (Sigma-Aldrich) , and 1x
mammalian protease inhibitor cocktail (Sigma-Aldrich). Proteins were separated using
SDS-PAGE and protein ubiquitination was measured via Western blot.

2.2.13 Immunoblotting of Ubiquitination
For immunoblotting, membranes were blocked in 5% goat serum for 1hr. All
primary antibodies were incubated for 1 hour at room temperature and visualized using
an HRP-conjugated secondary antibody and ECL reagents.

2.2.14 LC-MS/MS Analysis of Ubiquitination
DG75 cells were cultured, treated with MG132 and divided into two groups. One
group was treated with piceatannol as detailed above and the other group was treated with
DMSO control. The protein content was extracted and 40 mg portions were digested as
detailed before; chloroacetamide was used in place of ioadoacetamide. Ubiquitinated
peptides were enriched using UbiScan ubiquitin remnant antibody kit (Cell Signaling
Technology) according to manufacturer’s protocol, and the LC-MS analysis was carried
out as before.
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2.3 Results and Discussion

2.3.1 Polymac-Zr for Phosphopeptide Enrichment
We introduced recently PolyMAC-Ti for efficient capturing of
phosphopeptides26. In addition to titanium, zirconium is capable of effectively binding to
phosphate groups, and this property has been successfully explored for both
phosphopeptide enrichment19, 29 and DNA capturing30, 31 using solid supports. To further
explore the utilization of zirconium ion for phosphopeptide enrichment, we developed a
soluble nanopolymer-based reagent, PolyMAC-Zr (Figure 2.3.1), polyamidoamine
(PAMAM) generation 4 dendrimer functionalized with Zr4+ ions. Hydroxylamine groups
were attached to the dendrimer, which were used as the “handle” to capture the
dendrimer onto aldehyde-functionalized agarose beads through a rapid covalent reaction.
During phosphopeptide enrichment, a complex peptide mixture is incubated with the
PolyMAC-Zr reagent in solution, resulting in the rapid and selective binding of
phosphopeptides in the homogenous solution. The phophopeptide-bound PolyMAC-Zr
reagent is then isolated using the aldehyde-functionalized beads. Lastly, the bound
phosphopeptides are eluted off under basic conditions for mass spectrometric analysis.
The capability of the reagent to effectively enrich phosphopeptides was first evaluated
using a simple mixture containing angiotensin II and phosphorylated angiotensin II
(Figure 2.3.2), and then with a panel of peptides generated from phosphorylated ( αcasein, β-casein and ovalbumin) and unphosphorylated proteins (lactalbumin, βlactoglobulin, catalase, hemoglobin and bovine serum albumin). Before enrichment, the
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majority of peaks detected by MALDI-TOF analysis were non-phosphopeptides. After
the enrichment, only phosphopeptides were observed (Figure 2.3.3).
To evaluate the performance of the new reagent for use in a complex mixture, we
further tested it with a whole cell lysate generated from the human Burkitt’s lymphoma B
cell line, DG75. A 100 µg sample of the cell lysate was digested with trypsin and
subjected to phosphopeptide enrichment by PolyMAC-Zr. Among the various tested
loading buffer conditions, a solution consisting of 200 mM glycolic acid, 50%
acetonitrile and 1% trifluoroacetic acid was optimal for high selectivity and recovery.
The PolyMAC-Zr reagent captured over 1,200 unique phosphopeptides from 100 µg of
DG75 cell lysate with over 60% selectivity for phosphorylated peptides (Figure 2.3.4 a,
b). The overlap of identified phosphopeptides between any two experiments was
approximately 75%, demonstrating the excellent reproducibility of homogeneous capture
with PolyMAC-Zr (Figure 2.3.4 c), consistent with previous studies with PolyMAC-Ti26.
On the other hand, the overlap of phosphopeptides enriched by PolyMAC-Zr and
PolyMAC-Ti was less than 50% (Figure 1d), indicating each metal ion enriched a unique
set of phosphopeptides.

2.3.2 In-Depth Analyses of Syk-Dependent Phosphorylation in B-Cells
PolyMAC-Zr was used in combination with PolyMAC-Ti to investigate Sykdependent phosphorylation in B cells following anti-IgM stimulation of the BCR (Figure
2.3.5). Two populations of DG75 cells were grown in SILAC media containing either
“light” or “heavy” (13C6-labeled) arginine and lysine. One group of cells was treated with
the Syk inhibitor, piceatannol, while the other group was treated with DMSO as a control.
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Both sets were stimulated with anti-IgM antibody to activate the BCR signaling pathway.
Equal amount of protein (2.5 mg) extracted from each cell population were mixed and
digested with trypsin.
In order to reduce the sample complexity we used RPLC32 or HILIC25 in the first
dimension of peptide fractionation. HILIC and RPLC are complementary separation
methods25, 33 and we used PolyMAC-Zr to enrich phosphopeptides after HILIC fractions.
The orthogonality of RPLC was achieved by separating peptides at high (pH 8) and low
pH (pH 2.6) values in the two dimensions32, 34. Previously this has been successfully
applied for both phosphopeptide and non-phosphopeptide separations32, 34, 35. Each RPLC
fraction was enriched for phosphopeptides using PolyMAC-Zr or PolyMAC-Ti before the
LC-MS/MS analysis. Figure 2.3.6 summarizes the total number of phosphopeptides, the
number of unique phosphopeptides obtained from each fractionation approach and the
distribution of phosphopeptides in different fractions. As expected, the unique
phosphopeptides identified using PolyMAC-Zr versus PolyMAC-Ti demonstrated only
about 50% overlap (Figure 2.3.6.b). A total of 13,029 unique phosphopeptides
representing over 16,000 unique phosphorylation sites were identified in this study. The
distribution of serine, threonine and tyrosine phosphosites is illustrated in Figure 2.3.6 c.
The relative abundances of 0.05%, 10% and 90% have been reported for
phosphotyrosine, phosphothreonine and phosphoserine, respectively. Here we identified
437 (2.6%) phosphotyrosine, 2447 (15.1%) phosphothreonine and 13304 (82.2%)
phosphoserine sites. The relative abundances are close to expected values for
phosphothreonine and phosphoserine but significantly higher for phosphotyrosine. Such
differences have been reported in previous studies that utilized extensive fractionation to
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enable identification of low abundant proteins that are usually phosphorylated on tyrosine
residues10. We compared quantitatively the “light” to “heavy” ratios of identified
phosphopeptides between the piceatannol-treated and untreated samples to assess the
importance of Syk to BCR-stimulated phosphorylation. Out of 13,029 unique
phosphopeptides, 1,506 showed more than a 2-fold increase, whereas 2,340 showed more
than a 2-fold decrease by treatment with the inhibitor. These unique phosphopeptides
provided a list of 1,982 phosphorylation sites with increased phosphorylation from 1,049
proteins and 2,960 sites with decreased phosphorylation levels from 1,446 proteins.

2.3.3 Regulation of Cellular Functions by Syk Dependent Phosphorylation
In the presence of an antigen, B cell receptor (BCR) aggregates and transduces
signals to the cell interior by activating Src-family kinases Lyn, Blk and Fyn, as well as
tyrosine kinases Syk and BTK. These participate in signaling complexes that include
adaptor proteins such as CD19 and BLNK and signaling effectors such as PLC, PI3K
and VAV. Signals transduced through these components activate multiple downstream
signaling cascades, inducing changes in cellular metabolism, gene expression and
cytoskeletal organization. These signaling cascades can regulate survival, tolerance,
proliferation, or differentiation of B cells2, 36, 37. Therefore, it is important to understand
the Syk-dependent processes of these complicated signaling events. Elucidation of these
processes can be facilitated by examining signaling events with and without the inhibition
of Syk using piceatannol. Proteins directly involved in these pathways typically
demonstrate decreased levels of phosphorylation upon Syk inhibition. However, feedback
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loops and lack of activation of phosphatases may result in increased levels of
phosphorylation in some proteins36-38.
To further understand the Syk-dependent changes in phosphorylation, the nature
of upstream kinases were predicted based on the sequences of phosphorylation sites
using software developed in-house, as shown in Figure 2.3.7 a. A list of kinase motifs
was extracted from the human protein reference database (HPRD)39, and upstream
kinases were predicted for all the phosphorylation sites identified with changing
phosphorylation levels. The normalized fraction of phosphorylation sites for each kinase
is illustrated in Figure 2.3.7 a, where a positive value indicates the fraction of
phosphorylation sites with increased phosphorylation and a negative value indicates the
fraction of phosphorylation sites with decreased phosphorylation upon treatment with
piceatannol. According to the above analysis, calmodulin-dependent kinase motifs are
found only among the sites with decreased phosphorylation. Intracellular calcium levels
increase during BCR signaling1 and Syk inhibition interrupts proper signal propagation,40
which may lead to the decreased activity of calcium dependent kinases. AKT and NIMA
kinase motifs are represented only among sites with increased phosphorylation. AKT is
activated downstream of BCR engagement in B cells; therefore, a decrease in AKT
activity is expected upon Syk inhibition. However, this observed increase in
phosphorylation could be due to the fact that most cultured lymphoid cell lines, including
DG75, lack both PTEN and SHIP1 and have constitutively active Akt41-43. Furthermore,
there are significantly higher numbers of CDC-like kinase 1 (CLK1) and AMP-activated
protein kinase (AMPK) with decreased phosphorylation. AMPK is known to be activated
downstream of the TCR in a manner dependent on CaMKKs and the Zap-70 substrates
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LAT and SLP7644. CLK1 is a dual specificity kinase expressed in the nucleus that is
involved in mRNA splicing45. Serine/arginine rich proteins are known substrates for this
kinase46, and several such proteins show decreased phosphorylation levels in our study.
Interestingly, we identified RNA post-transcriptional modifications pathway as one of the
perturbed networks upon Syk inhibition (Figure 2.3.7 b, and Figure 2.3.8 a). Specifically,
mRNA spicing factors, ribonuclear proteins and splicing regulatory proteins show
significant changes in levels of phosphorylation.
Interestingly, Src-family kinases, polo-like kinase 1(PLK1), and ataxia
telangiectasia mutated kinase (ATM) substrate sites are enriched among sites with
increased phosphorylation. Syk and Src family kinases are known to participate in
signaling cross talk47 and may have non-redundant48 or opposing49 roles in some
pathways. Therefore, Syk inhibition may have affected cross talk between Syk and Src
kinases resulting in increased levels of Src family kinase-dependent phosphorylation.
PLK1, on the other hand, functions in centrosome maturation, spindle assembly and
cytokinesis. Prior experiments have revealed autophosphorylation-dependent centrosomal
localization of Syk4, 6, 50 and co-localization of Syk and PLK1 at mitotic spindle poles51.
Threonine phosphorylation on Syk by PLK1 has been reported to be a part of an antiapoptotic mechanism, and the disruption of the mechanism may have activated
alternative PLK1-dependent phosphorylation events51. Furthermore, we have identified
centrosome organization as one of the functions perturbed upon Syk inhibition (Figure
2.3.7 b and Figure 2.3.8 b).
A limitation in upstream kinase prediction is the lack of known consensus
sequences for the majority of kinases and therefore the study was restricted to a few

32
enzymes. Furthermore, the substrate specificities of many kinases overlap, making it
difficult to attribute specific phosphorylation events to a single kinase. Still, some of the
kinase motifs show significant enrichment among groups of sites with distinctive higher
or lower phosphorylation levels. On the other hand, functional annotation provides
complementary information that can be correlated with phosphorylation changes of
kinase specific sites. For example, we have identified NPM1, NUDC and BUB1B which
are PLK1 substrates during centrosome organization. Therefore it is likely that these
kinases are acting as nodes in various downstream pathways that are modulated by Syk in
B cells. Some of the important pathways and functions are summarized in Figure 2.3.7 b.
The function of Syk in the immune system has been widely studied52 and we observed
the B cell receptor (BCR) signaling pathway as the most perturbed canonical pathway
(Figure 2.3.9). Furthermore, other known Syk-dependent networks such as FcRIIB,
PI3K, PLC signaling, NFAT regulation2 and centrosome organization were also
observed. More interestingly, we identified RNA post transcriptional modification and
the ubiquitin proteasome pathway as novel potential Syk-dependent pathways.

2.3.4 Syk-Dependent Ubiquitination in B-cells
One of the most intriguing networks in our data annotation is the ubiquitin
proteasome pathway (Figure 2.3.10). We identified and quantified a significant number
of phosphorylated nodes that function in this pathway, including E1, E2, E3 ligases,
proteasome components, and deubiquitinases (DUBs). The proteins belonging to the
above categories are summarized in Figure 2.3.11 a with the SILAC fold change ratios
obtained for identified peptides. Among the different classes of proteins in the ubiquitin
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proteasome pathway identified in this study, DUBs are the most prominent group. The
majority of DUBs were found to contain significantly decreased levels of
phosphorylation on one or more sites after Syk inhibition, such as Y364 on ubiquitin
specific peptidase 10 (USP10). Deubiquitinases are tightly regulated both spatially and
temporally, similar to ubiquitin ligases, thus enabling careful control over cellular
signaling and protein stability53. Phosphorylation is thought to be a key regulatory
mechanism for DUBs, as was demonstrated by a recent study of the human
deubiquitinase DUBA being controlled through phosphorylation at S177 by casein kinase
(CK2)54 and USP25 has been reported as a Syk substrate55. This is the first report on the
regulation of ubiquitination by Syk.

2.3.5 Proteomics Analysis of Syk-dependent Ubiquitination
In order to identify ubiquitinated proteins modulated by Syk, DG75 cells were
treated with MG132 to inhibit the proteasome and half of the cells were also treated with
piceatannol to inhibit the Syk activity. An examination of global protein ubiquitination by
western blot analysis showed a substantial decrease in protein ubiquitination following
the treatment of cells with piceatannol (Fig. 2.3.11 b). After cell lysis and protein
digestion, the ubiquitinated peptides were enriched using an antibody raised against the
di-glycine motif, and the resulting peptides were identified using LC-MS/MS.
Quantification was achieved in a label-free manner using a synthetic peptide library56.
This examination resulted in the identification and quantification of over 1,300 unique
ubiquitination sites. Although the overall level of ubiquitination was increased, after
setting the cut-off values at two-fold changes based on the library peptide normalization,
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we found that 360 and 520 peptides showed decreased and increased ubiquitination
representing 282 and 372 proteins, respectively. It should be noted that anti-ubiquitin
antibody used for Western blots shows stronger signals for polyubiquitinated proteins
whereas antibody against diglycine residue does not distinguish between mono and
polyubiquitination. Hence the ubiquitin proteomics experiment may not perfectly match
the Western blot results. Our goal was to specifically identify proteins with decreased
ubiquitination upon Syk inhibition. A functional annotation was carried out for the
proteins with increased or decreased ubiquitination. IPA analyses revealed that the
proteins with functions in RNA post transcriptional modifications and nucleic acid
metabolism are prominent among proteins with decreased ubiquitination, illustrated in
figures 2.3.12 a and b respectively. For example, Pre-mRNA-processing-splicing factor 8
(PRPF8), heterogeneous nuclear ribonucleoprotein H3 (HNRNPH3), RNA-binding
protein 39 (RBM39) and U2 small nuclear ribonucleoprotein B (SNRPB2) are among
proteins functioning in RNA post transcriptional regulation specifically by RNA
processing and splicing with decreased ubiquitination levels upon Syk inhibition.
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2.4 Conclusions
Previous studies on Syk-dependent signaling events in B cells focused mainly on
tyrosine phosphorylation, thus limiting information on potentially diverse Syk functions
and downstream signaling events. With Syk being an upstream kinase within several
signaling cascades, there are numerous opportunities for serine/threonine phosphorylation
events that can be modulated by its kinase activity. Our integrated approach of using
complementary Ti- and Zr-based phosphopeptide enrichment with RPLC and HILIC
fractionation has led to identification of over 16,000 unique phosphorylation sites and
quantification of nearly 4,000 peptides with significant phosphorylation changes. The
annotation of corresponding proteins reiterated known Syk-dependent functions and
suggested novel potential networks. Furthermore, canonical pathway analysis suggested a
significant influence of Syk activity on ubiquitination network in B cells. The subsequent
examination of the dependence of ubiquitination on Syk activity was carried out and
among more than 1,300 ubiquitination sites identified, the data showed decreased
ubiquitination levels in RNA processing and splicing proteins in response to Syk
inhibition.
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Figure 2.1: PolyMAC Reagent
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Figure 2.2: Evaluation of PolyMAC-Zr Using a Simple Peptide Mixture. A peptide mixture
containing angiotensin II (m/z 1046) and phosphangiotensin II (m/z 1126) was enriched
with PolyMAC-Zr and analyzed by matrix assisted laser desorption ionization (MALDI)
time of flight (TOF)/TOF mass spectrometry. The peptide mixture before enrichment (a),
elution after enrichment (b), and the initial amount of angiotensin II (m/z 1046) spiked
into the elution (c)
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Figure 2.3: Evaluation of the Selectivity of PolyMAC-Zr. Using a mixture of trypsindigested α-casein, β-casein and ovalbumin (phosphoproteins), α-lactalbumin, βlactoglobulin, catalase, hemoglobin and bovine serum albumin (non-phosphoproteins).
The peptide mixture was enriched with PolyMAC-Zr and analyzed by matrix assisted
laser desorption ionization (MALDI) time of flight (TOF)/TOF mass spectrometry. (a)
Before enrichment, and with different phosphopeptide enrichment “enhancers” in the
loading buffer (b) 300 mM glycolic acid, (c) 100 mM glycolic acid, (d) 100 mM formic
acid, (e) 300 mM latic acid (f) 100 mM lactic acid, (g) 100 mM citric acid, (h) 200 mM
3-hydroxypropanoic acid. Evaluation of PolyMAC-Zr using digests of DG75 cell lysates.
(i) Comparison of three phosphopeptide enrichment experiments showing the number of
phosphopeptides enriched in each experiment and the number of non-phosphopeptides
identified in each experiment. (j) Comparison of PolyMAC-Zr and PolyMAC-Ti for the
number of phosphopeptides enriched and the selectivity. (k) Overlap of phosphopeptide
enrichment between any two PolyMAC-Zr experiments or PolyMAC-Zr and PolyMACTi experiments.
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Figure 2.4: Evaluation of PolyMAC-Zr
Using DG75 Cell Lysates. (a)
Comparison of three PolyMAC-Zr
phosphopeptide enrichment
experiments showing the number of
phosphopeptides enriched in each
experiment and the number of nonphosphopeptides identified in each
experiment. (b) Comparison of
PolyMAC-Zr and PolyMAC-Ti for the
number of phosphopeptides enriched
and the selectivity. (c) Phosphopeptide
identification overlap of
phosphopeptide enrichment between
any two PolyMAC-Zr experiments or
PolyMAC-Zr and PolyMAC-Ti
experiments.

Figure 2.5: The Work Flow for Examination of Syk-Dependent Phosphorylation in B-cells.
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Figure 2.6: The Summary of
B-Cell Phosphopeptide
Fractionation and Enrichment.
(a) Overall phosphopeptide
identification in each
separation-enrichment
combinations. Total number of
phosphopeptides was
calculated by adding the
number of phosphopeptides in
each fraction and the unique
phosphopeptides were
calculated by removing any
duplicate identification. (b)
The number of
phosphopeptides identified in
each fraction in three
separation and enrichment
combinations. RPLC and
HILIC fractions enriched by
PolyMAC-Zr, and RPLC
fractions enriched by
PolyMAC-Ti. (c) Upper panel
shows the phosphopeptide
overlap of RPLC fractions
enriched with PolyMAC-Ti
and PolyMAC-Zr. Lower
panel shows the overlap
between RPLC and HILIC
fractions both enriched with
PolyMAC-Zr. (d) The pie
chart shows the percentages of
serine, threonine and tyrosine
phosphosites identified in this
study.

Figure 2.7: Regulation of Cellular Networks by Syk dependent Phosphorylation. (a) Distribution of consensus kinase motifs within
the data set. (b) A summary of B cell functions perturbed by Syk inhibition.
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Figure 2.8: Syk dependent Cellular Networks (a) RNA Post transcriptional modifications protein network. The color bar indicates
Log2 (Heavy/Light) ratio for phosphorylation. (b) Centrosome organization protein network. The color bar indicates Log2
(Heavy/Light) ratio for phosphorylation
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Figure 2.9: B-cell Receptor Signaling Pathway and Phosphoproteins Perturbed by Syk
Inhibition. The color scheme red to green indicates phosphorylation increase and
decrease respectively.
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Figure 2.10: Protein Ubiquitination Pathway. The color scheme red to green indicates
phosphorylation increase and decrease respectively.

Figure 2.11: Syk dependent Ubiquitination (a) Phosphorylation on ubiquitin proteasome pathway proteins. The plot indicates the
SILAC fold changes (x axis) of E1, E2, E3 ligases, deubiquitinases and proteasome components. Positive and negative values
represent phosphorylation increase and decrease respectively. Western blots indicating Syk dependent ubiquitination. (b) Antiubiquitin Western Blot of proteins from DG75 B cells treated without (-) or with (+) piceatannol. GAPDH was used as the loading
control.
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Figure 2.12: Network Analysis of Ubiquitination Decreased Proteins. (a) RNA post transcriptional modification network (b)
Nucleotide metabolism network. Enzymes (blue), transcription regulators (green), peptidases (pink), transporters (purple),
kinases (yellow) and other proteins (orange). Protein names are given in the list of abbreviations in supplementary data.
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CHAPTER 3: SEQUENTIAL ENRICHMENT OF TYROSINE PHOSPHOPEPTIDES

3.1 Introduction
B cells are an important entity of the adaptive immune system and they are
characterized by the presence of the surface immunoglobulin known as the B cell
receptor (BCR) which is capable of recognizing a diverse range of foreign antigens1. The
activation of B cells through cross-linking of BCR by antigen engagement initiates
phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs).
According to current knowledge the tyrosine kinase, Syk and the Src-family kinase, Lyn
are the first molecules recruited to form this singling complex1, 2. In addition to Lyn and
Syk numerous adaptor proteins and effector proteins such as phospholipase C- (PLC),
phosphatidylinositide 3-kinase (PI3K), guanine nucleotide exchange factor Vav and Bcell linker protein (BLNK) are vital components in signaling complexes in B cell2. Thus
formed complex elicit many downstream pathways such as activation of Btk,
mobilization of Ca2+ ions and activation of NFAT pathway, PI3K, Akt and mTOR
pathways, Ras/MEK/ERK pathway and activation of NF-B through protein kinase C
(PKC), CARMA1, BCL10, and MALT11-4. It is well accepted that the tyrosine kinase
Syk and the Src family kinase, Lyn are at the top of these signaling cascades and there are
numerous accounts describing specific roles of these kinases in B-cells.
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Initially the signaling function of Syk was considered to be limited to
immunoreceptors of the adaptive immune system. However more recent discoveries have
reported Syk mediated signaling by the collagen receptor glycoprotein VI5, integrins6 and
C type lectins7 as well as roles for Syk in lymphatic vascular development8 and born
resorption by osteoclasts9 providing evidence for diverse functionality of Syk in cellular
environment extending beyond adaptive immune system. Lyn, on the other hand, is a Src
family member predominantly expressed in hematopoietic cells and known for its dual
activity in positively and negatively regulating cellular signaling10-12. In B cells, Lyn
phosphorylates several ITIM-containing inhibitory receptors, such as CD22 and Fc
receptor gamma IIb (FcγRIIb)12. Also it interacts with tyrosine phosphatases such as
SHP-1, SHP-2 or the inositol phosphatase SHIP-1 required to down regulate BCR
signaling12-14. Similar to Syk, Lyn also acts downstream of many other receptors such as
GM-CSF receptor15, FceRI16, Epo receptor17-19, c-kit20 and integrins21 in both positive
and negative regulatory functions.
One of the earliest events in BCR stimulation is the induction of tyrosine kinases.
It has been demonstrated that Syk deficient and Lyn deficient B cells have different
patterns of phosphorylation indicating that Syk and Lyn mediate different signaling
pathways after BCR stimulation22. This suggests that Syk and Lyn have distinct functions
and different sets of substrates. There are numerous reports detailing complementary and
opposing functions of Syk and Lyn in cellular pathways. For example, in Syk negative B
cells tyrosine phosphorylation on PLC was abolished resulting loss of both inositol
1,4,5-trisphosphate (IP3) generation and Ca2+ immobilization following BCR stimulation
whereas in Lyn negative cells, normal PLC induction and a slow increase in Ca2+ ion
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concentration has been observed22 showing that both these kinases have some role in the
process. Although the Ca2+ ion increase is slow in Lyn deficient cells, it is amplified and
prolonged and B cells from Lyn deficient mice are hyper-responsive to IgM cross-linking
leading to hyper-activation of ERK1, ERK2, MEK1 and c-Jun N terminal kinase and
show a hyper-proliferation response suggesting an inhibitory effect on BCR signaling by
Lyn. The negative regulatory effect of Lyn on BCR signaling is exerted in several
different ways. Upon BCR stimulation, kinases are recruited to the cross-linking site on
the plasma membrane and Syk becomes phosphorylated on Y317, Y342 and Y346
located in the linker region23. Phosphorylation on Y317 on Syk by Lyn strongly reduces
Ca2+ immobilization through PI-3K dependent pathway in a negative regulatory
mechanism23, 24. After BCR stimulation, Syk-receptor complex aggregates as patches on
the membrane and forms a cap at one pole of the cell. Syk is essential for the formation
and stabilization of tightly capped BCR complex at the plasma membrane. In the absence
of Lyn, Syk is still recruited to the cross-linked receptor but the receptor internalization is
impaired resulting a long-lived receptor-Syk complex at the plasma leading to prolonged
signaling25. Furthermore, the activation of AKT is regulated by Syk after BCR crosslinking and in Lyn deficient B-cells, AKT shows hyper-phosphorylation and enhanced
activity indicating opposing effects of Syk and Lyn on AKT activation26. The drug
sensitive CML cells acquire resistance to nilotinib upon coexpression of Syk and Lyn.
Lyn mediates the drug resistance through phosphorylation of Syk and Axl , on the other
hand, Syk mediates the drug resistance through phosphorylation of Lyn and Axl
indicating the complementary behavior of Lyn and Syk during CML cell drug
resistance27. The above examples describe the complementary and opposing roles of Syk
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and Lyn during BCR signaling as well as in other processes. Further it can be assumed
that with the diverse range of signaling processes that these two kinases participate,
similar roles in other receptor signaling events also.
This study was designed to further investigate the roles of Syk and Lyn in B-cells
at the proteomics level. In order to do that DT40 wild type, Syk deficient, Lyn deficient
and Syk and Lyn deficient cell lines were used. Phosphotyrosine peptides were enriched
in a sequential approach where in the first step the peptides were enriched with tyrosine
specific antibody beads and in the second step those peptides were re-enriched with
PolyMAC-Ti. Over 1000 phosphotyrosine sites were identified in this approach and
depending on the phosphorylation changes across the different samples the sites were
categorized into five different categories. Further analysis of these categories reaffirmed
known Syk and Lyn dependent cellular functions as well as suggested novel functions
and pathways in B-cells that are regulated by the above kinases.
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3.2 Methods

3.2.1 Isolation of Tyrosine Phosphopeptides from DG75 Cells
DG-75 cell culture was grown to 80% confluence in RPMI-1460 media
substituted with 10% inactivated FBS, 1% sodium pyruvate, 0.5%
streptomycin/penicillin, and 0.05% β-mercaptoethanol. Then the cells were washed with
PBS, collected, and frozen at -80 °C. Cells were lysed in 1 mL of lysis solution (50 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 1 mM sodium orthovanadate, 1x
phosphatase inhibitor cocktail (Sigma-Aldrich), 10 mM sodium fluoride) with sonication.
The resulting mixture was centrifuged at 16,100 × g for 10 minutes, and supernatant
containing soluble proteins was collected. The protein concentration was measured using
the BCA assay. DG-75 protein lysate was denatured and reduced in 50 mM trimethyl
ammounium bicarbonate containing 0.1% RapiGest (Waters) and 5 mM dithiothreitol for
30 minutes at 50 °C. The proteins were further alkylated in 20 mM iodoacetamide for 1
hour in the dark at room temperature, and digested with proteomics grade trypsin at 1:100
ratio overnight at 37 °C. The pH was adjusted below 3 and the sample was incubated for
40 minutes at 37 °C. The sample was centrifuged at 16,100 × g and supernatant was
collected. The sample was desalted with a Sep-Pak C18 column (Waters). The
enrichment of phosphopeptides was carried out using 100 µg samples, according to the
protocol described below.
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3.2.2 Enrichment of Tyrosine Phosphopeptides Using Anti-Phosphotyrosine Beads
The required amount of peptide sample was taken and dissolved in Tris-Cl pH 7.5
buffer and anti-phosphotyrosine antibody beads (PT66, Sigma-Aldrich) was added at a
ratio of 40 µl of slurry for 1 mg of protein. The mixture was incubated at 4oC overnight
with end-over-end rotation. The beads were washed with the lysis buffer twice and with
water once at 4oC, then the phosphotyrosine peptides were eluted three times with 0.1%
TFA and another three times with 0.1% TFA/50% acetonitrile mixture at room
temperature. The eluents were dried used for the secondary enrichment with PolyMACTi.

3.2.3 Enrichment of tyrosine Phosphopeptides Using PolyMAC-Ti
The peptide mixture was dissolved in 200 µl of the loading buffer (0.1%
trifluoroacetic acid and 50% acetonitrile), 5 nmol of PolyMAC-Ti was added to it and
incubated for 5 minutes at room temperature. Then 100 µl of capture buffer (3 mM
glycolic acid/300 mM HEPES buffer at pH 7.7) was added, to increase the pH above 6.3
and transferred to a non-stick tube containing 50 ul of magnetic hydrazide beads
(SIMAC). The sample was incubated for 10 minutes with shaking at room temperature
and the supernatant was removed. The beads were washed with 200 µl portions of
loading buffer and twice with washing buffer (100 mM acetic acid, 1% trifluoro acetic
acid, 80% acetonitrile). Then the phosphopeptides were eluted from the bead-bound
PolyMAC-Ti by incubating twice with 100 µl portions of 400 mM ammonium hydroxide
in 30% acetonitrile solution. During washing and elution each incubation step was carried
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out for 5 minutes with shaking. The samples were dried and used for LC-MS/MS
analysis.

3.2.4 Isolation of Tyrosine Phosphopeptides from DT40 Cell Lysate
DT40 cell culture was grown to 80% confluence in RPMI-1460 media substituted
with 10% inactivated FBS, 1% Chicken serum, 1% sodium pyruvate, 0.5%
streptomycin/penicillin, and 0.05% β-mercaptoethanol. Then the cells were washed with
PBS, collected, and frozen at -80 °C. Cells were lysed in 1 mL of lysis solution (50 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 1 mM sodium orthovanadate, 1x
phosphatase inhibitor cocktail (Sigma-Aldrich), 10 mM sodium fluoride) with sonication.
The resulting mixture was centrifuged at 16,100 × g for 10 minutes, and supernatant
containing soluble proteins was collected. The protein concentration was measured using
the BCA assay. The sample preparation for mass spectrometric analysis was carried out
as described above. Phosphotyrosine peptides were isolated as described above using 5
mg protein samples, with anti-phosphotyrosine antibody followed by PolyMAC-Ti
enrichment.
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3.2.5 LC-MS/MS analysis
Peptide samples were redissolved in 10 µl of 0.25% formic acid and injected into
an Eksigent nano LC Ultra 2D system. The reverse phase C18 was performed using an
in-house C18 capillary column packed with 5 µm C18 Magic bead resin (Michrom; 75
µm i.d. and 30 cm of bed length). The mobile phase buffer consisted of 0.1% formic acid
in ultra-pure water with the elution buffer of 0.1% formic acid in 100% CH3CN run over
a shallow linear gradient (from 2% CH3CN to 35% CH3CN) over 60 min with a flow rate
of 300 nl/min. The electrospray ionization emitter tip was generated on the packed
column with a laser puller (Model P-2000, Sutter Instrument Co.). The Eksigent Ultra 2D
HPLC system was coupled with a hybrid linear ion trap orbitrap mass spectrometer
(LTQ-Orbitrap Velos; Thermo Fisher). The mass spectrometer was operated in the data
dependent mode in which a full scan MS (from m/z 300 – 1700 with the resolution of 30,
000 at m/z 400) was followed by 20 MS/MS of the most abundant ions. Ions with charge
state +1 were excluded. The mass exclusion time was 90 s.

3.2.6 Database search
The LTQ-Orbitrap raw files were searched directly against chicken database using
SEQUEST or MASCOT on Proteome Discoverer (Version 1.3, Thermo Fisher).
Proteome Discoverer created DTA files from raw data files with minimum ion threshold
15 and absolute intensity threshold 50. Peptide precursor mass tolerance was set to 10
ppm, and MS/MS tolerance was set to 0.8 Da. Search criteria included a static
modification of cysteine residues of +57.0214 Da and a variable modification of
+15.9949 Da to include potential oxidation of methionine and a modification of +79.996
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on serine, threonine or tyrosine for the identification of phosphorylation. Searches were
performed with full tryptic digestion and allowed a maximum of two missed cleavages on
the peptides analyzed from the sequence database. False discovery rates (FDR) were set
to 1% for each analysis. Proteome discoverer generates a reverse “decoy” database from
the same protein database and any peptide passing the initial filtering parameters that
were derived from the decoy database and define as false positive identification. The
minimum cross correlation factor (Xcorr) filter was readjusted for each individual charge
state separately in order to optimally meet predominant target FDR of 1% based on the
number of random false-positive matches from the reveres “ decoy” database. Thus, each
dataset had its own passing parameters. The number of unique phosphopeptides and nonphosphopeptides identified were then counted using in-house software and compared.
Phosphorylation site localization from CID spectra was determined by PhosphoRS on
Proteome Discoverer 1.3. For quantitation, the same raw files were searched against a
database of a peptide library which was spiked into each sample before the LC-MS/MS
run.

3.2.7 Data Analysis and Quantification
A list of all the phosphotyrosine peptides identified was prepared and unique
peptides were extracted based on the m/z value and the charge state using an in-house
software. The site localizations were obtained from PhosphoRS assignments. Each
peptide list was normalized using the peptide library and a Log 2 ratio was expressed as
DT40 mutant/DT40 wild type for each peptide.
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3.2.8 Motif Analysis
In order to predict upstream kinases for identified phosphotyrosine sites, in-house
software was used and the kinase motifs listed on human protein reference database were
used.

3.2.9 Pathway Analysis
A list of proteins corresponding to peptides showing increased or decreased
phosphorylation was extracted. This list with decreased and increased phosphorylation
and the corresponding fold change ratios were submitted to Ingenuity Pathway Analysis
(IPA) (Ingenuity Systems). The IPA criteria were set to include only direct interactions.
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3.3 Results and Discussion

3.3.1 Development of Phosphotyrosine Peptide Enrichment Method
Tyrosine phosphorylation represents less than 1% of cellular phosphorylation
compared to serine and threonine posing a challenge in identification specifically in a
large scale phosphorpteomics experiments. This problem is usually circumvented by
employing anti-phosphotyrosine antibody based enrichment at protein or peptide level.
Although antibodies can enrich phosphotyrosine peptides efficiently over phosphoserine
and phosphothreonine, they capture a large number of non-phosphopeptides, as depicted
in Figure 1 a, the selectivity towards phosphotyrosine peptides is about 30%.
Phosphopeptides are generally difficult to analyze by mass spectrometry because they are
negatively charged and the electrospray is generally performed in positive mode. Also
phosphopeptides are not observed as intense peaks in the presence of nonphosphorylated
peptides owing to ion suppression effect. Therefore further reducing the amount of nonphosphopeptides in the sample improves the identification of phosphotyrosin peptides.
Hence it is common practice to use anti-phosphotyrosine antibody and phosphopeptide
enrichment in sequential manner to improve phosphotyrosine identification. We applied a
PolyMAC-Ti based enrichment to the sample after phosphotyrosine antibody enrichment
and this allowed us to significantly decrease the number of non-phosphopeptides and
increase the selectivity towards tyrosine phosphorylated peptides to 80% without
sacrificing the number of identifications but increasing the identification as the sample
size increases, which is demonstrated in figures 1b and c. Based on the above preliminary
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results this method was used to study tyrosine phosphorylation related to two major
kinases Syk and Lyn in B cells using Chicken B cell line DT40.

3.3.2 Syk and Lyn-based Tyrosine Phosphorylation in B-cells
Tyrosine kinase Syk and Src family kinase Lyn are at the top of the signaling
cascades in B-cells and activates many cellular pathways. DT40 cell line derived from
chicken B-cells and Syk, Lyn or double knock-out DT40 cell lines have been extensively
used to investigate downstream pathways of these kinases. Most of the previous studies
have been focused on understanding the tyrosine phosphorylation after BCR stimulation,
but now it is known that these kinases are involved in many other signaling events as
well. Therefore in this study was planned to understand the phosphorylation events of
these kinases using a proteomics approach without restricting to BCR signaling. DT40
wild type, Syk-/-, Lyn-/- and Syk-/-Lyn-/- cell lines were grown as detailed in previous
reports, cells were collected and treated with sodium orthovanadate to inhibit
phosphatases. The phosphatase inhibition is extensively used in studies related to
phosphoryloation in B-cells, as the treatment inhibits phosphatases transient
phosphorylation on substrate proteins can be preserved during the sample preparation
which helps identification of these phosphorylation sites in the mass spectrometer. The
cells were lysed, protein component was extracted, digested with trypsin and the sample
was incubated with anti-phosphotyrosine antibody. The peptides eluted from the antibody
beads were re-enriched with PolyMAC-Ti and a standard peptide library was spiked into
each peptide sample for quantification during the LC-MS/MS analysis. DT40 wild type
peptides were considered as the control and the other samples were quantified relative to
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the wild type sample. The quantitative changes of each phosphotyrosine site were
assessed across Syk, Lyn and double knockout cell lines. Based on the quantifications
the entire phosphotyrosine site list could be grouped into five major categories as shown
in figure 3a as Syk dependent, Lyn dependent, Syk and Lyn dependent, Syk or Lyn
dependent and Syk and Lyn independent. Phosphotyrosine sites that are grouped as Sykdependent showed decreased phosphorylation levels in Syk-/- DT40 cells and Syk-/-Lyn/- DT40 cells whereas increased or unchanged phosphorylation levels in Lyn-/- cells.
Lyn-dependent showed decreased phosphorylation levels in Lyn-/- DT40 cells and Syk-/Lyn-/- DT40 cells whereas increased or unchanged phosphorylation levels in Syk-/- cells.
Syk and Lyn-dependent sites showed decreased phosphorylation levels in both Syk-/- and
Lyn-/- cells as well as double knock out cell line. Syk or Lyn dependent sites showed
increased or unchanged phosphorylation levels in one of the cell lines and unchanged or
decreased phosphorylation levels in Syk-/-, Lyn-/- double negative cell line. The sites that
are not affected or showing increased phosphorylation levels with the loss of Syk and
Lyn are grouped as Syk and Lyn independent. As shown in figure 3a there were 522 Sykdependent phosphotyrosine sites, 234 Lyn-dependent phosphotyrosine sites, 266 Syk and
Lyn dependent sites, 58 Syk or Lyn dependent sites and 47 Syk and Lyn independent
sites. This observation is comparable with the anti phosphotyrosine western blot of the
cell lysates of the four cell lines used (Supplementary figure 1). Wild type cells show the
highest amount of tyrosine phosphorylation and it is closely followed by the Lyn- cell
line. This could be due to the loss of inhibitory effect of Lyn on Syk. Further supporting
this Syk- cell line shows a much lower phosphorylation level and as expected Lyn and
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Syk double negative cells show extremely low phosphorylation levels on the western
blot.

3.3.3 Consensus Motif Analysis
In order to further confirm Syk or Lyn dependency of these sites motif logos were
generated for the peptides in each category and shown in figure 3b-f. Syk substrate motifs
are characterized by acidic residues around the tyrosine site and the Lyn substrate motifs
are characterized with a hydrophobic residue before the tyrosine and acidic residue after
the tyrosine. (Supplementary figure 2) Direct Syk and Lyn substrate sites are expected to
find in the Syk dependent and Lyn dependent data sets respectively. Syk-dependent sites
generated EDEEDYEESEE as a prominent motif which is quite comparable with the
accepted Syk motif EDEE(D/E)YEESEE. Lyn dependent site motifs showed
EEEEA(I/L/V)YESLEKK as a prominent motif which is comparable with the accepted
Lyn motif IYE. Syk and Lyn-dependent sites highlight (L/D/E)Y(D/E) with both acidic
or hydrophobic residues at the phosphorylation motif indicating potential Syk or Lyn
dependent site motif is much closer to Syk consensus sequence mainly consisted of
acidic amino acids. Syk and Lyn independent site motif contains acidic amino acids as
well as many other amino acids without really projecting a specific kinase substrate
motif.

3.3.4 Known Syk and Lyn Substrates and Sites
As expected some of the known substrates of Syk and Lyn can be observed
among Syk dependent and Lyn dependent protein groups showing phosphorylation on the
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previously reported sites. Y759 of PLCg-2, Y330 of PRKCAB and Y330 of BTK has
been shown as Syk substrates in previous reports. In addition, HCLS1 shows a
homologus site for Human HCLS1 Y3340 site. Further, BLNK and Cbl shows two pY
sites though they are different from the homologous reported sites for human. There are
several Lyn substrates that have also been identified among the Lyn dependent pY sites.
Y340 of BTK, Lyn auto-phosphorylation site of Lyn, Y21 of PTPN6. Also two sites on
PAG1 and DOK2 has also been reported which are previously reported Lyn substrates
but the sites we identify are slightly different from what is previously reported.

3.3.5 Kinases and Phosphatases
Among the proteins that were modulated as mentioned above there were a
significant number of kinases and phosphatases. The peptides corresponding to those are
shown in figure 4a, b and supplementary figure 2. There were 12 tyrosine kinases, 31
serine/threonine kinases, and 3 dual specificity kinases among the molecules identified
with tyrosine phosphorylation. Further there were 13 tyrosine phosphatases and 2
serine/threonine phosphatases.

3.3.6 Tyrosine Kinases in B-cells
The ordered activation of three different non-receptor tyrosine kinases; Lyn, Syk
and Burton Tyrosine Kinase (BTK) is required for proper BCR signal transduction. The
activation and recruitment of Lyn and Syk to the BCR complex influence the activity of
BTK through PI-3K and PI(3,4,5)P3 production. Inhibition of PI-3K or BTK impair
many downstream signaling events in B cells indicating the significance of BTK in signal
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propagation. Cross-linking BCR induces phosphorylation on Y223 and Y551 on BTK,
Syk and Lyn dependent regulation of these sites has been previously reported28-30. Human
Y551 (Chicken Y549) is an activation site for BTK during BCR signaling. The mutation
of Y551 abrogated calcium immobilization in B-cells and it has been suggested that
transphosphorylation of BTK Y551 is essential for BCR signaling and it is mediated
through the concerted action of Lyn and Syk29, 30. Further Syk dependent regulation of
BTK is known to mediate through BLNK28. We have correctly identified this site as a
Syk or Lyn dependent phosphosite in this study. Phosphorylation on Y551 activates BTK
and induces autophosphorylation at Y223 (Chicken Y220) which is known to be
controlled by Lyn and Syk and it has been correctly classified under Syk and Lyn
dependent sites in this study. Among the other identified BTK sites Y40 and Y334 are
Lyn dependent and Syk dependent respectively. For both these sites upstream
kinase/phophotase prediction yielded as a potential Src site or TC-PTP site. However the
amino acid composition around the tyrosine residue deviates from typical Lyn or Syk
consensus sequence. Y225 (Chicken Y222) has been identified as a Syk and Lyn
dependent site, although any upstream kinase has not been reported to this site as well as
upstream kinase/phosphatase prediction does not report a potential kinase or phosphatase.
The other two identified sites, Y86 and Y318 are unique to chicken BTK and these sites
are Lyn dependent and Syk or Lyn dependent respectively. The analysis of BTK
phosphorylation revealed Syk and Lyn dependent nature of Y551 and Y223 as reported
previously and our study further indicates that Y40, Y86, Y225, Y334 on BTK may also
be regulated by Syk and Lyn.
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Since the data provides evidence for Syk and Lyn dependent BTK regulation
under the experimental conditions, to further confirm, we searched for known BTK
substrate phosphorylation sites. BTK phosphorylates four tyrosine residues on PLCg2
during BCR signaling31. Out of those Y753 (Chicken Y754), Y759 and Y1217 have been
identified in this study. Y759 is Syk dependent whereasY753 and Y1217 are Syk and
Lyn dependent. BTK controls sustained calcium signaling in B-cells via site specific
phosphorylation at Y753 and Y759 which are located at SH2-SH3 linker region32.
Glycoprotein VI also stimulates Y753 and Y759 phosphorylation through BTK33. Further
BTK mediates chemokine controlled migration of B-cells via PLCg2 Y759
phosphorylation34. Y248 (Chicken Y246) of GTF2I is another BTK substrate site that we
have identified. Phosphorylation of Y248 of GTF2I is thought contribute to
transcriptional activation linking BCR receptor engagement to modulation of gene
expression35.
Lyn was thought to be the only Src family kinase present in DT40 cells and a
recent study reported detection of Fyn mRNA in Lyn deficient DT40 cells at about 10 20% level compared to Lyn in wild type DT40 cells36. It has also been postulated Fyn
may contribute to positively regulate BCR signaling under these conditions. Interestingly
in this study we have identified activation sites Y420 and Y28 on Fyn both showing Lyn
dependent phosphorylation. Further Lyn dependent phosphorylation of autocatalytic sites
of FER (Y714), EphA2 (Y772), and a motif very similar sequence in EphA2
autocatalytic site on Ephb3 has been identified in our study.
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3.3.7 Serine/Threonine Kinases in B-cells
There are several serine threonine kinases that are reported to be directly
phosphorylated by Syk or Lyn; MAP4K1 and PKACA are Syk substrates whereas
PKACD is a Lyn substrate. In addition there are many cellular pathways that are
modulated by Syk and Lyn including BCR signaling through serine/threonine kinases.
One of the main groups of serine/threonine kinases identified in this study is MAP
kinases mainly show Syk and Lyn independent phosphorylation in the activation loop
tyrosine residue and in certain cases the phosphorylation on the nearby threonine residue
has also been identified. Upon BCR engagement tyrosine kinases activates Ras-GTP
complex which in turn activates the MAP kinase kinase c-Raf initiating MAP kinase
cascade leading to activation of transcription factors. The serine/threonine kinase c-Raf
activates dual specificity MAP kinase kinases (Mek1 and 2). Mek1 and Mek2
phosphorylates activation loop threonine and tyrosine residues simultaneously and
activates transcription factors; Extracellular-regulated kinase-1 and 2(ERK1 and 2). In
addition Ras-MEKK1 pathway activates JNK1/2 and p38 via Mek4/7 and Mek 3/5/6
respectively. In this study we have identified ERK2, p38, JNK 2 and 3 with Syk and Lyn
independent phosphorylation and it can be postulated that this change is mediated
through a common upstream protein such as Ras. It has been reported that during IL5
signaling in eosinophil, MAP signaling cascade is activated by Jak2 and Lyn through
tyrosine phosphorylation on Ras37. Therefore we believe that the observed
phosphorylation changes in the aforementioned proteins may be modulated through a
kinase such as Jak2.
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Cyclin dependent kinases (CDKs) are considered to be the closest relatives of
MAPKs and there are numerous CDKs identified in this study which are also seem to be
independent of both Syk and Lyn. Colocalization and coimmunoprecipitation studies
have provided evidence for direct association between CDK2 and Lyn in ara-C treated
cells38. Further it has been reported that Lyn phosphorylates Tyr15 of CDK2 leading to
inhibition of CDK2 activity. These findings suggest that the association of Lyn and
CDK2 in ara-C-treated cells may contribute to regulation of CDK2-dependent cell cycle
checkpoints. In addition it is known that CDK is inhibited in Syk dependent tumor
suppression mechanism39. In this study CDKs show phosphorylation at the activation site
in a Syk and Lyn independent manner. Therefore it can be postulated that inhibitory
phosphorylation on CDKs are directly or indirectly regulated by Syk and Lyn whereas
activation is independent.

3.3.8 Tyrosine Phosphatases in B-cells
Lyn deficient B-cells are hyper responsive to receptor stimulation, also these cells
showed elevated MAPK activation, enhanced calcium flux and hyper activation of AKT
suggesting a negative role for Lyn in BCR signaling12. The negative regulatory effects of
Lyn are mediated through phosphorylation on two main inhibitory receptors; FcgRIIb1
and CD2212. Lyn phosphorylates FcgRIIb1 at Y292 which in turn recruits SHIP-1 leading
to a cascade of negative regulatory events. CD22, Lyn and SHP-1 form a regulatory loop
in B-cells where Lyn phosphorylates ITIM domain of CD22 leading to SHP-1
recruitment mediating suppressive effects of CD22 on MAPK activation and Calcium
flux. During our study we have identified Lyn dependent phosphorylation sites on both
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SHIP-1 and SHP1. SHP-1 Y536 is known to be phosphorylated by Lyn. Along with
Y536 we have identified Lyn dependent phosphorylation on SHP-1 Y64, Y 301, and
Y564 also. Phosphorylation on Y536 and 564 by Src kinase have been reported to
activate SHP-1 and we believe that all the above site are in Lyn phosphorylation motifs
and potential Lyn sites which might be happening as a part of the regulatory mechanism.
In addition we have identified Y856 on SHIP-1 with Lyn dependent phosphorylation and
Y1022 shows a Syk and Lyn dependent phosphorylation. Studies show that the SH2domain of SHIP1 can bind to the C-terminus of the SHIP1 molecule via Y1022
phosphorylation and this interaction regulates the association between different forms of
SHIP1 and Ig-α40. Also it has been suggested that proteins such as DOK1 and SHC
interact with Y1022 phosphorylated SHIP-1 during SHIP-1 dependent cell migration41. It
has been identified that Y1020 is one of the main contact sites for the SHCphosphotyrosine binding domain and Lck phosphorylates these sites in T-cells42.
Another important group of tyrosine phosphates that have been identified is
receptor tyrosine phosphatases. CD45/PTPRC has been shown to be an essential
regulator of T- and B-cell antigen receptor signaling1, 14. It functions through either direct
interaction with components of the antigen receptor complexes or by activating various
Src family kinases required for the antigen receptor signaling. Regulation of Lyn activity
by dephosphorylating negative and positive activation sites of Lyn by CD45 has been
reported43 but Lyn phosphorylation of CD45 has not been reported. Y880 of CD45 show
Lyn dependent phosphorylation change however this site has not been reported before.
Y1015 shows a Syk dependent phosphorylation change however based on the motif it is
more like a JAK2 substrate site. CD45 also suppresses JAK kinases and functions as a
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negative regulator of cytokine receptor signaling44. Further Y705, Y978 and Y1073 show
Syk and Lyn dependent phosphorylation changes. In B-cells CD45 activity is
compensated by CD148/PTPRJ14, 45 and we have identified Y1045 as a Lyn dependent
site. Similar to CD45-deficient mice, B cells from CD148-deficient mice show partially
blocked B cell development and activation as well as greater phosphorylation of the
inhibitory C terminus of Lyn14, 45.

3.3.9 Adapter Proteins in B-cells
Once Lyn, Syk and BTK are activated, progression of signaling requires tyrosine
phosphorylation dependent activation of a number of adaptor molecules46, 47. We have
identified numerous B-cell adaptor proteins as shown in figure 3c, with phosphorylation
site changes in Syk and Lyn dependent manner. Interestingly there are several
phosphorylation sites of common proteins such as VAV2, PAG1 changing independent
of Syk and Lyn. PLCg2 is an adaptor protein in the BCR signalosome, the recruitment
and activation of PLCg2 and elevation of Ca2+ ion concentration are important secondary
steps in BCR signaling. We have identified several BTK substrate sites on PLCg2 in this
study and discussed above. PAG1 is another important adaptor protein in B- and T-cells
which negatively regulates the receptor signaling. PAG1 is phosphorylated in resting Tcells by Fyn and the phosphorylation decreases in response to TCR signaling46, 47. Y163
and Y181 show increased phosphorylation with loss of either kinase and this is
interesting because PAG1 is phosphorylated in the absence of the receptor signal48. These
sites are necessary for suppressing c-Src activity by acting as scaffolds for c-Src binding
in cancer cells to down regulate its activity independent of Csk. B-cell adaptor for
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PI3K(PIK3AP1 or BCAP) is another B-cell adaptor protein that we have identified with
multiple phosphorylation sites. Among those both Y594 and Y694 have been identified
to be Syk and Lyn dependent and the above C-terminal tyrosine sites are known to be
phosphorylated by Abl49. CBL is an E3 ligase that negatively regulates many signaling
pathways that are triggered by cell surface receptor activation. Syk is negatively
regulated by CBL by ubiquitination and degradation upon phosphorylation on Y323 by
Lyn50. We have identified Y371 and Y674 as Syk and Lyn dependent phosphorylation
sites. EGFR and insulin receptor have been suggested as regulators for Y371
phosphorylation leading to block the ubiquitin ligase activity of CBL51. On the other hand
Y674 has been suggested to be regulated by Syk52. Syk and Lyn are upstream kinases in
many cellular pathways and functional networks in B-cells. It is well accepted that the
signaling cascades starting from cell surface receptors and propagates via Syk and Lyn to
modulate various cellular pathways via kinases, phosphatases and various adaptor
proteins.

3.3.10 Pathway Analysis
The protein lists were extracted from the five categories of phosphotyrosine sites
(Syk dependent, Lyn dependent etc.) and the pathways that are modulated in each
category was investigated. As expected BCR signaling as well as other prominent Bcells pathways such as PI3K signaling and FcRIIB were identified in all lists. Previously
we showed Syk dependent ubiquitination in DG75 cells and we have again identified
protein ubiquitination as a major Syk dependent pathway. More interesting we identified
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Syk dependent mTOR signaling and Lyn dependent Leukocyte extravasation as
prominent pathways which are described below.

3.3.11 Syk-dependent mTOR Signaling
In B-cells mTOR positively regulates protein synthesis by activating two major
signaling pathways, p70S6K/RPS6 and 4E-BP1/eIF4E and turn controls cap-dependent
translation of mRNAs with 5’ untranslated regions which is a characteristic of transcripts
of oncogenic proteins53. mTOR is constitively active in acute myeloid leukemia (AML)
cells and important in AML cell survival. Inhibition of mTOR in AML cells has been
associated with both anti-proliferating and pro-differentiation effects54. In B-cell
lymphoma Syk is a critical regulator of mTOR activity55, 56. Syk inhibition reduces
viability and promotes differentiation in AML cells. However the downstream signaling
effectors of Syk are not known yet in this process. AKT is an upstream kinase for mTOR,
and in our study we have identified AKT family protein, AKT2. AKT2 shows Syk
dependent phosphorylation on Y240 in THFPQFSySASIRE sequence which is highly
conserved across species. However the upstream kinase for this site has not been
reported. In addition we have identified perturbation in regulation of eIF4 and p70S6K
signaling pathways which are directly downstream of mTOR, again in a Syk dependent
manner, further supporting Syk dependent regulation of mTOR. Figure 6 illustrates the
connectivity between mTOR, and regulatory pathways of eIF4 and p70SK through the
proteins identified in our study.
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3.3.12 Lyn-dependent Leukocyte Extravasation
Leukocyte extravasation is a primary component in cellular immune response in
which leukocytes migrate from blood to tissue. This process is associated with cell to cell
communication, hematological system development and immune cell trafficking. Lyn as
well as other Src family kinases are known to be involved in leukocyte extravasation
though this function of Lyn has not been extensively investigated .A recent report
identifies Lyn as a redox sensor that mediates initial neutrophil recruitment to
inflammatory sites. Lyn activation is dependent on wound-derived H2O2 after tissue
injury. Inhibition of Lyn has reduced the recruitment of neutrophils to inflammatory site.
For the enhanced permeability and leukocyte extravasation, tyrosine phosphorylation of
catenin and VE-cadherin are necessary. Further it has been reported that phosphorylation
of different tyrosine of VE-cadherin is regulated in an opposing manner where not only
phosphorylation but also dephosphorylation by phosphatases such as SHP-2 plays a role
in regulating leukocyte extravasation. In our study we have identified several prominent
proteins in leukocyte extravasation such as catenin, focal adhesion kinase, and PTPN11
(SHP-2). SHP-2 shows Lyn dependent phosphorylation sites with a potential Lyn
substrate motif SARVyENVG. The network of proteins in Lyn dependent Leukocyte
extravasation is illustrated in figure 7.
.
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3.4 Conclusions
Previous studies have reported regulation of BCR signaling and other cellular
pathways by Syk and Lyn in compensatory as well as opposing manner. However
investigation of individual phosphorylation events and pathways provided only limited
information on downstream effects of these two upstream kinases. Therefore we
performed a proteomics level investigation on Syk and Lyn dependent pathways in Bcells using multiple DT40 cell lines; wild type, Syk deficient, Lyn deficient, and Syk and
Lyn double deficient. To further enhance phosphotyrosine identificatio , we sequentially
enriched peptide samples with phosphotyrosine antibody beads and PolyMAC-Ti. This
approach enabled us to identify and quantify 1218 tyrosine phosphorylated peptides
across four cell lines. We grouped these phosphotyrosine peptides into five categories as
Syk dependent, Lyn dependent, Syk and Lyn dependent, Syk or Lyn dependent and
Independent based on the phosphorylation changes across cell lines. The examination of
phosphotyrosine sites on kinases, phosphatases and adaptor proteins suggested potential
regulatory events mediated by Syk, Lyn or other kinases in B-cells. Furthermore,
canonical pathway analysis revealed Syk dependent mTOR pathway and Lyn dependent
leukocyte extravasation.
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Figure 3.1: Basic Evaluation of Sequential Enrichment. Basic Evaluation of Antibodybased Enrichment and Antibody-PolyMAC Sequential Enrichment for Tyrosine
Phosphorylated Peptides. (a) Antibody-based enrichment, (b) antibody-PolyMAC-Ti
based sequential enrichment indicating the numbers of total peptide (blue),
phosphopeptides (red) and tyrosine phosphorylated peptides (green)(c) comparison of
tyrosine phosphorylated peptide enrichment between antibody and antibody-PolyMACTi sequential enrichment methods.
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Figure 3.2: Experimental Work-flow. DT40 wild type, DT40 Syk-/-, DT40 Lyn-/and DT40 Syk-/-Lyn-/- double knockout cell lines were cultured. Proteins were
extracted and digested. The peptide sample was first enriched with anti
phosphotyrosine antibody beads, then by PolyMAC-Ti. A standard peptide library
was spiked in before LC-MS/MS for quantitation.
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Figure 3.3: Phosphotyrosine Site Classification and Motif Analysis. (a)Based on
quantitative changes on each phosphotyrosine residue, the sites are classified into five
categories as, (i) Syk dependent, (ii) Lyn dependent, (iii) Syk and Lyn dependent, (iv)
Syk or Lyn dependent and (v) Syk and Lyn independent. The graph demonstrates the
numbers of phosphotyrosine sites (blue) and proteins (red) under each category. (b)- (f)
Motif logos for the above five categories of phosphotyrosine sites

Figure 3.4: Tyrosine Phosphorylation
Changes in Kinases, Phosphatase and
Adapter proteins. Quantitative changes
are summarized for each
phosphotyrosine site for (1) DT40 Lyn/-, (2) DT40 Syk-/- and (3) DT40 Syk-/, Lyn-/- cells. Number (No.) refers to
the phosphosite indicated in the
supplementary table. (a)
Phosphotyrosine sites on kinases, (b)
phosphotyrosine sites on phosphatases.
Kinases and phosphatases are grouped
based on their specificity; y: tyrosine
kinase/phosphatase, s: serine/threonine
kinase/phosphatase, d: dual specificity
kinase/phosphatase, o: other kinases, l:
lipid phosphatases, (c) Tyrosine
phosphorylation changes in adapter
proteins that may interact with above
kinases and phosphatases. Red
indicates more than 2-fold increase and
green indicates more than 2-fold
decrease compared to the control
sample.
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Figure 3.5: mTOR Pathway
Proteins. Red: translation
regulator, Green: enzyme,
Pink: transcription regulator,
Orange: transmembrane
protein, Blue: kinase, Purple:
phosphatase, Brown: protein
complex, Yellow: protein
group, Gray: other
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Figure 3.6: Leukocyte
Extravasation Pathway
Proteins. Red: translation
regulator, Green: enzyme,
Pink: transcription
regulator, Orange:
transmembrane protein,
Blue: kinase, Purple:
phosphatase, Brown:
protein complex, Yellow:
protein group, Gray: other
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PROTEIN FRACTIONATION USING IMAC-Cu

4.1 Introduction
The proteomes of mammalian cells, tissues, and body fluids are complex and
display a wide dynamic range of protein concentrations. The number of protein
sequences in humans is estimated to be approximately 100,000, and possibly the number
may increase by 10-100 times with different isoforms1. In addition the dynamic range of
protein concentrations2 can span over seven orders of magnitude in cells and ten orders of
magnitudes in plasma3. Consequently, analysis of the proteome is a much more
challenging task than that of the human genome and the challenge is to provide sufficient
amount of information in experimental datasets to match the underlying complexity.
Mass spectrometry has evolved as the state of the art technology for proteomics analysis
due to its speed, sensitivity, accuracy and ability to couple with chromatographic
techniques4. In spite of new technologies, analysis of complex biological mixtures, ability
to quantify separated protein species, sufficient sensitivity for proteins of low abundance,
quantification over a wide dynamic range, ability to analyze protein complexes, and high
throughput applications is not yet fulfilled. In addition, there is an added layer of
complexity to biological samples due to the high background and matrix components
which is a significant challenge in secretome analysis.
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The proteins secreted by particular types of cells, the so-called secretomes, play
important roles in regulation of many physiological processes via paracraine or autocrine
mechanisms, and they are of increasing interest as potential biomarkers and therapeutic
targets in disease5, 6. Investigation of secreted proteins is quite challenging due to
technical difficulties associated with analysis such as (i) low protein concentrations due
to their high dilution in body fluids or cell culture media, (ii) masking and contamination
of the secretome by cytoplasmic or other normally non-secreted proteins released
following cell lysis and death, and (iii) masking by serum proteins (i.e. fetal bovine
serum) normally present in the culture media7, 8.
Proteomics profiling is a relevant approach to biomarker discovery extensively
utilized in secretome analysis. Advances in techniques based on liquid chromatography
and two dimensional polyacrylamide gel electrophoresis in combination with mass
spectrometry have significantly facilitated the challenging detection of secreted proteins9
However, there is no stand-alone technique that can satisfactorily reduce the complexity
of protein samples. Therefore many new approaches have been developed to address the
challenges present in proteome analysis. In this context protein fractionation methods
have become pivotal in reducing sample complexity. 2D gel electrophoresis and
chromatography are widely used to fractionate protein samples. Since it was first
introduced10, 2D gel electrophoresis has evolved and become a powerful technique for
protein separation as well as the method of choice for differential protein expression
analysis. In 2D gel electrophoresis proteins are separated based on isoelectric point and
molecular weight in the two dimensions. This technique has an excellent resolving
power, so it is possible to visualize over 10,000 spots corresponding to over 1,000
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proteins, inclusing multiple spots that contain different molecular forms of the same
protein11. Nevertheless, it suffers from several major limitations related to
reproducibility12, poor representation of low abundant proteins13 and, proteins at the
extremes of acidity, basicity size and hydrophobicity14, and difficulties in automation of
gel-based techniques15. Moreover, the comigration of multiple proteins in a single spot
makes quantification difficult.
Due to limitations in 2D-gel electrophoresis, recent developmental efforts have
been mainly focused on chromatographic techniques. A wide range of physical and
chemical properties of proteins can be used fractionate complex protein samples such as
cell lysates and serum. Physical properties such as molecular weight, shape and charge as
well as chemical properties such as isoelectric point (pI), hydrophobicity, and affinity to
various ligands are commonly used in separation techniques at present16. There is a wide
variety of chromatographic methods using different properties of proteins to fractionate
proteins16-18. For example reverse phase (RPC) and hydrophobic interaction (HIC)
chromatography use hydrophorbic interactions between proteins and the stationary phase,
ion exchange chromatography is based on the charge of proteins, size exclusion
chromatography uses the differences in the size of proteins and affinity chromatography
utilize the interaction between proteins and various affinity ligands mounted on the
stationary phase. Each separation method demonstrates strengths and weaknesses. RPC
and HIC provide higher resolving power to smaller proteins (> 30000 Da) and peptides
than larger proteins. However, their mobile phases may cause protein denaturation
leading to precipitation or stronger adsorption and making it more difficult to elute the
proteins. Ion exchange chromatography (ICX) uses fairly mild elution conditions,
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allowing the proteins retain their native conformations. In addition, ion exchange resins
are very robust and can be used for hundreds of separations. The main disadvantages of
ICX resins are their poor selectivity and tendency to adsorb to either positively or
negatively charged proteins at the initial pH condition. In size exclusion chromatography
(SEC) the sample does not interact with the stationary phase, instead, the stationary phase
acts as a molecular sieve. However SEC provides the lowest resolution and lowest
capacity while also causing the highest dilution of samples.
The basic principle of affinity chromatography is based on the ability of proteins
to bind selectively and reversibly to a complementary molecule attached to a solid
support16, 19. Thus, proteins that do not possess complementary binding sites for the
affinity ligands pass directly through the column or can be eluted easily in early fractions.
The bound proteins are then eluted in the reverse order of the strength of the interaction.
Although antibodies directed against specific proteins or a group of proteins remain the
most popular affinity method, there are numerous other methods that have been
developed over the years. These methods include, lectin affinity for glycoproteins20-23
and, immobilized metal affinity chromatography (IMAC) containing nickel for histidine
tagged proteins24 or gallium for phosphoproteins25.
Immobilized metal affinity chromatography was first introduced in 1975 with the
initial aim of isolating nucleotides. Later, IMAC was used to immobilize proteins
including enzymes, antibodies, and recombinant proteins. Currently, IMAC-Ni is
extensively used to purify histidine tagged proteins, and IMAC-Fe is commonly used to
enrich phosphopeptides. In several instances IMAC functionalized with metals such as
Zn, Ni, Cu and Co has been used to investigate the mouse liver metalloproteome and
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classify proteins based on metal binding and non-binding properties. Furthermore, IMAC
has been used to isolate specific groups of metal binding proteins such as
metallothionine, prion proteins, matrilysin, and non-heme iron containing
metalloproteins. While studying metal-protein interaction with different metals
immobilized on IMAC, we observed that Cu2+ demonstrated a unique ability to capture
over 98% of the protein component of cell lysate and serum samples. Furthermore, it was
capable of successfully isolating secreted proteins over FASP from the complex matrix.
This suggested that copper – protein interaction can be applied to capture proteins from
complex mixtures and matrices and subsequently fractionate to identify low abundant
proteins. In chapter 4, we describe the development of IMAC-Cu based protein
fractionation method and its application to identify low abundant proteins in secretome.
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4.2 Methods

4.2.1 Preparation of Protein Samples
The concentrations of all protein samples were measured using BCA assay before
mixing with IMAC-Cu beads for capturing experiments. Standard protein mixtures: 1
mg/ml solutions of bovine serum albumin, β-lactaglobulin, catalase, β-casein and
ovalbumin were prepared separately and equal amounts were mixed to obtain standard
protein mixtures. Human and Swine serum samples: Serum sample aliquots were stored
in -80oC and thawed on ice before use. Serum samples were diluted twenty times with the
loading buffer before mixing with the IMAC-Cu beads. HEK 293 cell lysates: HEK 293
cells were grown in DMEM (high glucose) media supplemented with 10% FBS and 1%
penicillin/streptavidin. The cells were collected at 80% confluence, washed with PBS and
pelleted. The cell pellets were stored in -80oC until use. Binding buffer was added to the
cell pellet and lysed with homogenizer using short pulses. The sample was centrifuged
and the supernatant was collected for further experiments.

4.2.2 Preparation of Secreted Protein Samples
AGS cells were plated on sterile petridishes and cultured in DMEM containing
heat inactivated FCS (10%) at 37 oC and 5% CO2 to 80% confluence. Then the cells were
washed with serum and phenolred free DMEM media. The cells were infected with
Helicobacter piroli strain 26695 at M.O.I 100 in serum and phenolred free media (pH
5.0) for 8 hours. The supernatant was collected, passed through a 0.22 m filter to
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remove detached cells and bacteria. The samples were centrifuged at 4oC for 20 minutes
at 15000 rpm.

4.2.3 Preparation of IMAC-Cu Beads
Charging IMAC beads with the metal was carried out according to the instruction
given in the product manual. Briefly, 250 ul of the slurry was pipetted into a spin column.
The storage solution was removed by centrifugation using a bench top centrifuge for 1
minute. Then the beads were resuspended in distilled water by vortexing for 10 seconds
and centrifuged to remove water. This step was repeated three times. Next the beads were
washed with equilibration buffer (50 mM sodium acetate, 300 mM NaCl, pH 4) twice. 50
mM Copper (II) sulfate solution was added to beads and mixed for 10 minutes. Again the
beads were washed with equilibration buffer twice and distilled water thrice. Finally the
beads were washed with the binding buffer once.

4.2.4 Protein Capture by IMAC-Cu
Protein sample (maximum amount 1 mg) was dissolved in binding buffer (250 l)
and loaded onto the IMAC-Cu beads in the spin column. The sample was briefly votexed
and put in the shaker for 10 minutes at room temperature. The flow-through was
collected into a 1.5 ml tube.

4.2.5 SDS-PAGE Gel
2% volume of the above flow-through was taken and 2.5 l of LDS buffer and 1 l
of 200 mM dithiotretol were added. The final sample volume was adjusted to 10 l using
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nano-pure water. The protein mixtures were boiled at 95oC for 5 min and loaded onto
12% Bis-tris SDS-PAGE gel and the chamber was filled with 1X MOPS buffer. Then
proteins were separated on the ges at 170V for 1 hour.

4.2.6 Gel Staining
The gel was removed from the gel cassette and washed in nano-pure water for 30
minutes. Then it was washed with fixing solution (50% ethanol and 10% glacial acitic
acid) for 10 minutes. Next the gel was washed in rinsing solution (50% ethanol) for 5
minutes and nano-pure water for another 5 minutes. The gel was washed with 0.02%
sodium thiosulphate solution for 2 minutes and another 5 minutes. Next the gel was
stained in 0.1% silver nitrate solution of 20 minutes. After several short water washes, the
gel was developed using the developing solution (2% sodium carbonate, 0.04%
formaldehyde, 0.08% sodium thiosulfate). Finally gel was washed with 1% acetic acid
solution and nano-pure water.

4.2.7 Off-line Protein Fractionation
Off-line fractionation was carried out on a Agillent-1100 HPLC system using
ProPac IMAC-10 column (Thermo) functionalized with Cu2+ following the instructions
given in the product manual. Buffer A: 20 mM HEPES, 0.3 M NaCl, pH 7 and buffer B:
20 mM HEPES, 0.3 M NaCl, 50 mM imidazole (Sigma-Aldrich, BioUltra), pH 7.
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Table 1: Gradient Profile
Time

%B

0.0
5.0
5.5
10.0
10.5
15.0
15.5
20.0
20.5
25.0
25.5
30.0
30.5
35.0
35.5
40.0
40.5
45.0
45.5
50.0
50.5
55.0

0.0
0.0
10.0
10.0
15.0
15.0
17.5
17.5
20.0
20.0
25.0
25.0
30.0
30.0
40.0
40.0
50.0
50.0
75.0
75.0
100.0
100.0

Flow rate
(ml/min)
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00

Maximum
pressure
200
200
200
200
200
200
200
200
200
200
200
200
200
200
200
200
200
200
200
200
200
200

4.2.8 LC-MS/MS Analysis
Peptide samples were redissolved in 10 µl of 0.25% formic acid and injected into
an Eksigent nano LC Ultra 2D system. The reverse phase C18 was performed using an
in-house C18 capillary column packed with 5 µm C18 Magic bead resin (Michrom; 75
µm i.d. and 30 cm of bed length). The mobile phase buffer consisted of 0.1% formic acid
in ultra-pure water with the elution buffer of 0.1% formic acid in 100% CH3CN run over
a shallow linear gradient (from 2% CH3CN to 35% CH3CN) over 60 min with a flow rate
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of 300 nl/min. The electrospray ionization emitter tip was generated on the packed
column with a laser puller (Model P-2000, Sutter Instrument Co.). The Eksigent Ultra 2D
HPLC system was coupled with a hybrid linear ion trap orbitrap mass spectrometer
(LTQ-Orbitrap Velos; Thermo Fisher). The mass spectrometer was operated in the data
dependent mode in which a full scan MS (from m/z 300 – 1700 with the resolution of 30,
000 at m/z 400) was followed by 20 MS/MS of the most abundant ions. Ions with charge
state +1 were excluded. The mass exclusion time was 90 s.

4.2.9 Database Search
The LTQ-Orbitrap raw files were searched directly against human database using
SEQUEST HT Proteome Discoverer (Version 1.4, Thermo Fisher). Proteome Discoverer
created DTA files from raw data files with minimum ion threshold 15 and absolute
intensity threshold 50. Peptide precursor mass tolerance was set to 10 ppm, and MS/MS
tolerance was set to 0.8 Da. Search criteria included a static modification of cysteine
residues of +57.0214 Da and a variable modification of +15.9949 Da to include potential
oxidation of methionine Searches were performed with full tryptic digestion and allowed
a maximum of two missed cleavages on the peptides analyzed from the sequence
database. False discovery rates (FDR) were set to 1% for each analysis. Proteome
discoverer generates a reverse “decoy” database from the same protein database and any
peptide passing the initial filtering parameters that were derived from the decoy database
and define as false positive identification. The minimum cross correlation factor (Xcorr)
filter was readjusted for each individual charge state separately in order to optimally meet
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predominant target FDR of 1% based on the number of random false-positive matches
from the reveres “ decoy” database. Thus, each dataset had its own passing parameters.

4.2.10 Bioinformatics
The list of proteins obtained upon analysis of secreted protein samples was
subjected to gene ontology component analysis using Gene Ontology enRIchment
anaLysis and visuaLizAtion tool (GOrilla)26, 27 and interaction networks were generated
using String 9.1 protein-protein interaction prediction tool28 .
.
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4.3 Results and Discussion

4.3.1 Protein Capture by IMAC-Cu
Affinity chromatography was first introduced for enzyme purification and then it
was extended to receptor proteins, immunoglobulins, glycoconjugates, nucleotides and
even to whole cells and cell fragments29. In affinity chromatography the interaction
between protein and a specific affinity ligand on the stationary phase is used. The ligand
and protein interacts reversibly through a combination of electrostatic, hyrdoporbic as
well as short range Van der Waals forces and hydrogen bonding29. On the other hand
immobilized metal affinity chromatography (IMAC) relies on formation of weak
coordinate bonds between immobilized metal and the protein30. The interaction used in
IMAC depends on the formation of coordinated complexes between the metal ions and
the electron donor groups on the protein surface. Histidine shows the strongest interaction
with immobilized transition metals in which the electron donor groups on the imidazole
ring of histidine forms the strong coordination complexes with transition metals and the
actual protein retention on IMAC is directly correlated to the availability of histidine
residues31. In addition cystidine contributes to the metal protein interaction through thiol
groups and aromatic side chains of trypsin, phenylalanine, and tyrosine can also interact
with metal ions. Since all proteins contain these amino acid residues, it is expected that
all proteins are capable of binding to IMAC columns providing an affinity
chromatographic method that can be used to retain a significant fraction of the proteome
and separate based on the degree of interaction.
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Therefore, first we investigated the protein retention capability of different metals
using IMAC beads. IMAC beads containing iminodiacetic acid (IDA) as the metal
chelator, were functionalized with several metal ions that are commonly found in
biological systems, transition metals: Copper(II), Zinc(II), Manganese(II), Iron(III),
Cobalt(II), Nickel(II), and Titanium(IV) and non-transition metals Calcium(II) and
Magnesium(II). Then equal amounts of protein samples were loaded on to the beads,
incubated and the flow through was analyzed. Figure 1 shows the gel images of the flow
through analysis for both cell lysate and serum samples and they demonstrate that Cu(II)
processes a unique ability to capture majority of proteins while the other metals show
varying degree of capturing ability. According to previous studies, high molecular weight
region of a serum gel is mainly consisted of -glubulins and they interact with metal ions
in the order of Cu2+> Ni2+>Zn2+>Co2+. This same pattern persists in the gel image of the
serum sample further supporting our experimental data. In addition it has been reported
that Zn2+ requires two vicinal histidine residues on the protein surface for binding, Ni2+
requires at least two histidine residues and Cu2+ requires only one histidine residue on the
protein surface further supporting our observation of unique protein capture by IMACCu.

4.3.2 Evaluation of Protein Capture Efficiency of IMAC-Cu
Based on BCA assay, we observed over 98% protein capture by IMAC-Cu for
both cell lysate and serum samples. In order to further evaluate the protein capture
efficiency of IMAC-Cu, we used human serum samples due to two reasons; (i) the
availability of previously published data of serum protein capture by IMAC (ii)
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availability of serum protein depletion kits for highly abundant proteins encompassing
>99% of the serum which would enable comparison of protein capture by IMAC.
Therefore we incubated human serum samples with IMAC functionalized with the
aforementioned metals as well as high abundant protein depletion antibody beads as a
positive control and IMAC without any immobilized metal as a negative control. The
flow-through from each of the above experiments was collected, digested and analyzed in
the mass spectrometer with a spiked in peptide library for quantification. Each protein
was quantified related to human serum sample. Figure 2 indicates the percentage of
remaining protein amount in the flow-through after capture by IMAC-Cu, Ni, Zn and Co.
It is clearly visible that the protein captures by IMAC-Cu is comparable with the antibody
beads and the other metals show protein capture in the order of Ni2+>Zn2+>Co2+ as
inferred based on previous reports. The above results further support that IMAC-Cu
shows the best capture for proteins providing the highest protein adsorption do develop a
more general protein fractionation method.

4.3.3 Protein Fractionation on IMAC-Cu
Three possible mechanisms for immobilized metal ion chromatography have been
proposed; ion exchange, ligand exchange and hydrophobic interaction. The primary
binding mode for proteins on to IMAC is considered to be ligand exchange. It has been
reported that nitrogen containing ligands such as ammonia and tris salts reduce the
affinity to metal chelate column for proteins indicating the sensitivity to amine groups.
Therefore primary binding sites for of proteins are nitrogen containing ligand such as the
N-terminal amino acid, histidine, arginine, lysine, glutamine, asparagine or exposed
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amide nitrogen. This is further supported by the fact that basic proteins are strongly
retained on the column and the proteins can be successfully eluted using nitrogen
containing ligands such as imidazole and glycine. The increase in the affinity of the
proteins for the metal chelate as the pH increases also suggests that uncharged amino
groups are the species that interact with the metal ion. In addition acidic proteins are
weekly retained on the column and at acidic pH values the primary binding mode of
proteins to IMAC is thought to be predominantly by ion exchange. However the
hydrophobic interactions are not a significant mode of binding because even with high
salt concentrations have not shown any significant effect on protein binding to IMAC
columns.
Therefore, to get a basic understanding of which elution system to be optimized
we first investigated to fractionate proteins with linear pH gradient and imidazole
gradient. Some of the representative chromatograms are shown in the figure 3. Based on
that, pH elution from 7 to 4 did not elute all the proteins (Figure 3a). Although the
separation was not clearly visible, imidazole gradient elution from with 50 mM imidazole
could elute all the proteins in the sample (Figure 3b). In previous studies it has been
shown that the strong protein retention ability of IMAC-Cu across a wide pH range from
3.2 to 8.2 with a percentage retention to be about 93% at pH 8.1 and 88% at pH 7.2. The
most commonly used approach to elute proteins from IMAC columns is adding imidazole
to the elution buffer. Imidazole completes with the proteins that are bound through
nitrogen ligands to the metal ion. Therefore we used 20 mM HEPES, 0.3 M NaCl, pH 7
solution as buffer A and 20 mM HEPES, 0.3 M NaCl, 50 mM imidazole, pH 7 as buffer
B. We initially tested gradient elutions to separate proteins on the IMAC-Cu column
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which are shown in Figure 4. Figure 4a shows 40 minute linear gradient above with 1 mg
of cell lysate. The peak at 1.3 minutes probably represents proteins that do not bind to
IMAC-Cu column or weakly binding proteins. Figure 4b shows-step wise elution with
the above mentioned buffer B. With the step-wise gradient we were able to observe well
separated groups of proteins compared to linear gradient.

4.3.4 Evaluation of Ability to Identify Low Abundance Proteins
The main goal of protein fractionation was to simplify the sample and identify
low abundance proteins. Therefore after fractionation we analyzed some selected
fractions using LC-MS/MS and compared with the cell lysate which is demonstrated in
the figure 5. The spectral count values were obtained from a comprehensive list of cell
lysate proteins published recently32 and we plotted them against the molecular weight of
each identified protein in cell lysate and the fractions. It can be observed that there is a
trend towards lower spectral counts in the fractions. This is more visible in the insert in
which the percentage of identified proteins at different ranges of spectral counts has been
illustrated. Further in the fractions, there are about 500 more proteins that are not in the
published list we used and we believe they are very low abundance proteins that cannot
be easily identified.
Further we separated a human serum sample using the same step gradient as
above and one peak was analyzed as shown in figure 6a. Again the list was searched
against a recently published list33 of estimated concentrations of serum proteins. Analysis
of serum in LC-MS/MS reports about 1 proteins and the fraction analysed reported about
500 proteins. The overlap between the identified proteins are shown in the figure 6b.
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Figure 6c demonstrates the concentration profile for the proteins identified in the selected
fraction compared to the proteins identified in the direct analysis of serum. It can be
observed that the proteins identified in the fraction have relatively lower concentrations.
Further out of the five hundred proteins that we identified in the fraction only about one
hundred proteins can be found in the aforementioned list of serum proteins. Therefore we
believe most of the proteins we have identified in the in the fraction are low abundance in
the serum sample.

4.3.5 Analysis of Secreted Proteins
After identifying low abundance proteins from both cell lysate and serum samples
using IMAC-Cu based fractionation, we applied the same method to separate a sample of
secreted proteins collected after infection of AGS cells with Helicobacter pylori. These
samples have very low protein concentrations at microgram per milliliter level. In
addition the various chemical components in the cell culture media and serum proteins
make it difficult to capture and identify low abundance secreted proteins. Due to strong
protein capture and separation capability of IMAC-Cu we were able to identify
approximately one thousand proteins and about 20% of these were identified as
extracellular proteins by the gene ontology component analysis26, 27 which is illustrated in
figure 7. According to the above analysis, the sample is mainly enriched for proteins in
extracellular region, extracellular organelle, membrane bound vesicles, and extracellular
vesicle exosome which is indicated by the relatively higher p-value. The extracellular
proteins identified were further analyzed using String 9 protein-protein interaction
prediction tool28 and the interaction network generated is shown in figure 8. It highlights
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proteins such as cytokines and chemokines that are directly related to immune responses.
Further it includes low abundance proteins such as interleukin 834 and 1835 which are
known to mediate immune responses.
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4.4 Conclusions
We observed that IMAC-Cu can capture over 98% of proteins from both cell
lysates and serum samples. Based on that, we developed a method to identify low
abundance proteins in complex biological samples using an IMAC-Cu column on an
HPLC system. Initially we investigated the protein fractionation capability of the column
using both cell lysate and human serum. We obtained the best protein separation using a
step-wise gradient and the bound proteins were eluted by changing the imidazole
concentration in the elution buffer. We applied this method to separate a sample of
secreted proteins and nearly one thousand proteins were identified including low
abundance cytokines and chemokines.

106
4.5 References
(1)

Peng, J.; Gygi, S. P. J Mass Spectrom 2001, 36, 1083-1091.

(2)

Corthals, G. L.; Wasinger, V. C.; Hochstrasser, D. F.; Sanchez, J. C.
Electrophoresis 2000, 21, 1104-1115.

(3)

Anderson, N. L.; Anderson, N. G. Mol Cell Proteomics 2002, 1, 845-867.

(4)

Picotti, P.; Bodenmiller, B.; Mueller, L. N.; Domon, B.; Aebersold, R. Cell 2009,
138, 795-806.

(5)

Stastna, M.; Van Eyk, J. E. Circ Cardiovasc Genet, 5, o8-o18.

(6)

Stastna, M.; Van Eyk, J. E. Proteomics, 12, 722-735.

(7)

Chevallet, M.; Diemer, H.; Van Dorssealer, A.; Villiers, C.; Rabilloud, T.
Proteomics 2007, 7, 1757-1770.

(8)

Mbeunkui, F.; Fodstad, O.; Pannell, L. K. J Proteome Res 2006, 5, 899-906.

(9)

Kulasingam, V.; Diamandis, E. P. Nat Clin Pract Oncol 2008, 5, 588-599.

(10)

O'Farrell, P. H. J Biol Chem 1975, 250, 4007-4021.

(11)

Schulze, W. X.; Usadel, B. Annu Rev Plant Biol 2010, 61, 491-516.

(12)

Lilley, K. S.; Razzaq, A.; Dupree, P. Curr Opin Chem Biol 2002, 6, 46-50.

(13)

Gygi, S. P.; Corthals, G. L.; Zhang, Y.; Rochon, Y.; Aebersold, R. Proc Natl
Acad Sci U S A 2000, 97, 9390-9395.

(14)

Ong, S. E.; Pandey, A. Biomol Eng 2001, 18, 195-205.

(15)

Tonge, R.; Shaw, J.; Middleton, B.; Rowlinson, R.; Rayner, S.; Young, J.;
Pognan, F.; Hawkins, E.; Currie, I.; Davison, M. Proteomics 2001, 1, 377-396.

(16)

Issaq, H. J.; Conrads, T. P.; Janini, G. M.; Veenstra, T. D. Electrophoresis 2002,
23, 3048-3061.

(17)

Abdallah, C.; Dumas-Gaudot, E.; Renaut, J.; Sergeant, K. Int J Plant Genomics
2012, 2012, 494572.

(18)

Ly, L.; Wasinger, V. C. Proteomics 2011, 11, 513-534.

107
(19)

Lee, W. C.; Lee, K. H. Anal Biochem 2004, 324, 1-10.

(20)

Lefebvre, T.; Cieniewski, C.; Lemoine, J.; Guerardel, Y.; Leroy, Y.; Zanetta, J.
P.; Michalski, J. C. Biochem J 2001, 360, 179-188.

(21)

Machuka, J.; Okeola, O. G. J Agric Food Chem 2000, 48, 2296-2299.

(22)

Mansour, M. H. J Parasitol 1996, 82, 586-593.

(23)

Young, N. M.; Brisson, J. R.; Kelly, J.; Watson, D. C.; Tessier, L.; Lanthier, P.
H.; Jarrell, H. C.; Cadotte, N.; St Michael, F.; Aberg, E.; Szymanski, C. M. J Biol
Chem 2002, 277, 42530-42539.

(24)

Ji, J.; Chakraborty, A.; Geng, M.; Zhang, X.; Amini, A.; Bina, M.; Regnier, F. J
Chromatogr B Biomed Sci Appl 2000, 745, 197-210.

(25)

Posewitz, M. C.; Tempst, P. Anal Chem 1999, 71, 2883-2892.

(26)

Eden, E.; Lipson, D.; Yogev, S.; Yakhini, Z. PLoS Comput Biol 2007, 3, e39.

(27)

Eden, E.; Navon, R.; Steinfeld, I.; Lipson, D.; Yakhini, Z. BMC Bioinformatics
2009, 10, 48.

(28)

Franceschini, A.; Szklarczyk, D.; Frankild, S.; Kuhn, M.; Simonovic, M.; Roth,
A.; Lin, J.; Minguez, P.; Bork, P.; von Mering, C.; Jensen, L. J. Nucleic Acids Res
2013, 41, D808-815.

(29)

Hage, D. S.; Kao, P. C. Anal Chem 1991, 63, 586-595.

(30)

Porath, J. J Chromatogr 1988, 443, 3-11.

(31)

Liao, S. M.; Du, Q. S.; Meng, J. Z.; Pang, Z. W.; Huang, R. B. Chem Cent J 2013,
7, 44.

(32)

Fonslow, B. R.; Stein, B. D.; Webb, K. J.; Xu, T.; Choi, J.; Park, S. K.; Yates, J.
R., 3rd Nat Methods 2013, 10, 54-56.

(33)

Farrah, T.; Deutsch, E. W.; Omenn, G. S.; Campbell, D. S.; Sun, Z.; Bletz, J. A.;
Mallick, P.; Katz, J. E.; Malmstrom, J.; Ossola, R.; Watts, J. D.; Lin, B.; Zhang,
H.; Moritz, R. L.; Aebersold, R. Mol Cell Proteomics 2011, 10, M110 006353.

(34)

Bickel, M. J Periodontol 1993, 64, 456-460.

(35)

Gracie, J. A.; Robertson, S. E.; McInnes, I. B. J Leukoc Biol 2003, 73, 213-224.

IMAC-Co

IMAC-Fe

IMAC-Mn

IMAC-Zn

Cell Lysate

(b)
IMAC-Ni

IMAC-Co

IMAC-Fe

IMAC-Mn

IMAC-Zn

Human Serum

IMAC-Ti

IMAC-Mg
IMAC-Ca

IMAC-Cu

IMAC

Serum

IMAC-Ti

IMAC-Mg

IMAC-Ca

IMAC-Ni

IMAC-Cu

IMAC

Serum

Figure 4.1: Protein Capture by IMAC. Protein samples were loaded on to IMAC beads functionalized with different metals
(a) Cell lysate, (b) Human serum.
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Figure 4.3: Protein Elution from IMAC-Cu Column. (a) pH gradient from pH 7 to 4
(b) imidazole gradient from 0 mM to 50 mM

Figure 4.4: Protein Elution from IMAC-Cu Column with Imidazole Gradients. Buffer A: 20 mM HEPES, 0.3 M NaCl, pH 7,
Buffer B: 20 mM HEPES, 0.3 M NaCl, 50 mM imidazole, pH 7 (a) linear gradient (b) step-wise gradient
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Figure 4.5: Identification of Low Abundance Proteins from Cell Lysate. Log
(spectral count) vs. Log (molecular weight) was plotted for the proteins identified.
The insert shows the distribution of proteins across different ranges of spectral
counts for the proteins identified in the fraction marked with a box in 4b

Figure 4.6: Identification of Low Abundance Proteins from Human Serum. Log (estimated concentration) was plotted for
each identified protein. (a) step-wise gradient elution (b) overlap between direct serum analysis and the proteins identified in
the fraction marked with a box in 6a (c) the concentration distribution of proteins in direct serum analysis and the marked
fraction
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4.7: Cell Component Analysis
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4.8: Interaction Network of Cytokines and Chemokines in Immune Response
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ABSTRACT: Engagement of the B cell receptor for antigen
(BCR) leads to immune responses through a cascade of
intracellular signaling events. Most studies to date have
focused on the BCR and protein tyrosine phosphorylation.
Because spleen tyrosine kinase, Syk, is an upstream kinase in
multiple BCR-regulated signaling pathways, it also aﬀects
many downstream events that are modulated through the
phosphorylation of proteins on serine and threonine residues.
Here, we report a novel phosphopeptide enrichment strategy
and its application to a comprehensive quantitative phosphoproteomics analysis of Syk-dependent downstream signaling
events in B cells, focusing on serine and threonine
phosphorylation. Using a combination of the Syk inhibitor piceatannol, SILAC quantiﬁcation, peptide fractionation, and
complementary PolyMAC-Ti and PolyMAC-Zr enrichment techniques, we analyzed changes in BCR-stimulated protein
phosphorylation that were dependent on the activity of Syk. We identiﬁed and quantiﬁed over 13 000 unique phosphopeptides,
with a large percentage dependent on Syk activity in BCR-stimulated B cells. Our results not only conﬁrmed many known
functions of Syk, but more importantly, suggested many novel roles, including in the ubiquitin proteasome pathway, that warrant
further exploration.

B

The involvement of Syk in the pathogenesis of allergy,
autoimmune diseases, carcinoma and hematological malignancies has made it an important therapeutic target.2,4−6 Thus,
knowledge of the downstream pathways that mediate the
diverse functions of Syk are of considerable interest. Because
Syk is a tyrosine kinase, most studies have focused on Sykdependent tyrosine phosphorylation,7 which is largely limited
to immediate downstream signaling events and direct
substrates.8 Since Syk functions upstream of multiple pathways
of which serine/threonine kinases (e.g., PKC, Erk, Akt, etc.) are
major components, changes in its activity would be expected to
aﬀect many downstream events regulated by protein
phosphorylation on serines and threonines. This study was
designed to identify Syk-dependent downstream pathways in
activated B cells at the proteomics level, focusing mainly on
such serine and threonine phosphorylation events.
Mass spectrometry is the major tool for analyzing protein
phosphorylation in a high-throughput manner. Phosphopeptide
enrichment is a necessary prerequisite in phosphoproteomics as
a result of the low stoichiometry of protein phosphorylation

cells are a vital component of the adaptive immune
system that recognize foreign antigens through a cell
surface immunoglobulin known as the B cell receptor (BCR)
for antigen.1 B cell activation through BCR stimulation results
in proliferation and diﬀerentiation of B cells to form both
antibody-producing and memory cells. Cross-linking the BCR
by antigen engagement initiates phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) by the Srcfamily kinase, Lyn, and subsequent recruitment of the tyrosine
kinase, Syk. Multiple adaptor proteins and eﬀector proteins,
including the B cell linker protein BLNK, the guanine
nucleotide exchange factor Vav, phospholipase C-γ (PLCγ),
and phosphatidylinositide 3-kinase (PI3K), associate to form
signaling complexes2 that trigger downstream pathways such as
activation of Btk, mobilization of Ca2+,3 and activation of the
Ras/MEK/ERK pathway. The interaction between a phosphorylated ITAM and the SH2 domains of Syk, coupled with
the phosphorylation of the kinase on tyrosine, is essentially
required for all BCR-mediated signaling events.
The contribution of Syk to the adaptive immune response in
B cells is well-known and characterized. However, studies have
also identiﬁed a large number of diverse biological functions for
Syk, including cellular adhesion, phagocytosis, osteoclast
maturation, platelet activation, and vascular development.2
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Zr was added to it and incubated for 10 min. Then 250 μL of
capture buﬀer (300 mM HEPES buﬀer at pH 7.7) was added to
increase the pH above 6.3, and the mixture was transferred to a
spin column (Boca Scientiﬁc) containing 50 μL of Carbolink
coupling agarose gel (Thermo Scientiﬁc). The samples were
incubated for 10 min and centrifuged. The gel was washed with
loading buﬀer, washing buﬀer (100 mM acetic acid, 1%
triﬂuoroacetic acid, 80% acetonitrile), and water, then the
phosphopeptides were eluted with 400 mM ammonium
hydroxide.
Growing DG75 Cells in SILAC “Heavy” and “Light”
Media. For SILAC experiments, cells were grown to 50%
conﬂuency in SILAC RPMI-1640 media (Gibco) substituted
with 10% dialyzed inactivated FBS (Sigma-Aldrich), 1% sodium
pyruvate, 0.5% streptomycin/penicillin, 0.05% 2-mercaptoethanol, and either L-lysine and L-arginine for “light” samples or
13
C6-L-arginine and 13C6-L-lysine (Isotec) for “heavy” samples in
5% CO2 at 37 °C.
Piceatannol Treatment and IgM Pathway Stimulation.
The cell cultures were plated at a density of 2 × 107 cells/mL
and treated with piceatannol at a concentration of 50 μg/mL.
Then the cells were incubated at 37 °C for 30 min. The B cell
receptor signaling pathway was stimulated by treating the cells
with the anti-IgM antibody at a concentration of 10 μg/mL and
incubated at 4 °C for 15 min. The cells were lysed, and the
protein components were extracted and equally divided into
three portions to carry out the rest of the procedure as a single
experiment.
Sample Fractionation and Phosphopeptide Enrichment. Samples of “heavy” and “light” labeled whole cell
extracts (2.5 mg each) were normalized, mixed, and digested
with trypsin. The peptide sample was injected into an Agilent
1100 HPLC system and separated using either a 4.6 mm × 150
mm XBridge BEH C18, 3.5 μm particle reversed-phase liquid
chromatography (RPLC) column (Waters) or a 4.6 mm × 200
mm Polyhydroxyethyl A, 5 μm particle hydrophilic interaction
chromatography (HILIC) column (PolyLC Inc.). For the
HILIC fractionation, the 5 mg peptide sample was dissolved in
2 mL of solvent B (0.1% formic acid in acetonitrile), and the
sample was injected in 90% solvent B at a ﬂow rate of 0.1 mL/
min. Solvent A consisted of 0.1% formic acid in water. After
loading the sample, the column was washed with 90% solvent B
for 15 min at 0.5 mL/min ﬂow rate. Peptides were eluted in an
85% B to 65% B gradient for 40 min, followed by 65% B to
20% B gradient for 20 min at the same ﬂow rate. For the RPLC
fractionation, the 5 mg peptide sample was dissolved in 4 mL of
solvent A (10 mM TMAB in water, pH 8), and the sample was
injected in 98% solvent A at a ﬂow rate of 0.5 mL/min. After
loading the sample, the column was washed with 98% solvent A
for 10 min at a 1 mL/min ﬂow rate. Peptides were eluted over
98% A to 60% A gradient for 60 min at 0.5 mL/min ﬂow rate
(solvent B used for elution was 10 mM TMAB in acetonitrile,
pH 8). For each separation, 20 fractions were collected. For the
two sets of RPLC fractions, phosphopeptide enrichment was
carried out with PolyMAC-Zr and PolyMAC-Ti, whereas the
phosphopeptides in HILIC fractions were enriched only with
PolyMAC-Zr.
LTQ-Orbitrap Analysis. Peptide samples were redissolved
in 10 μL of 0.25% formic acid and injected into the Eksigent
nano LC Ultra 2D system. The reversed-phase C18 was
performed using an in-house C-18 capillary column packed
with 5 μm C18 Magic bead resin (Michrom; 75 μm i.d. and 12
cm of bed length). The mobile phase buﬀer consisted of 0.1%

9,10

and the low abundance of phosphoproteins.
Many diﬀerent
approaches have been employed for phosphopeptide enrichment 11 and can be categorized mainly under aﬃnity
puriﬁcation,10,12−20 chemical derivatization,21,22 and chromatographic separation. 23−25 The most popular enrichment
approaches, immobilized metal ion aﬃnity chromatography
(IMAC)13−16 and metal oxide aﬃnity chromatography
(MOAC),17−20 chelate phosphopeptides to an aﬃnity group
mounted on a solid support. This heterogeneous condition can
lead to poor binding accessibility and low reproducibility.
Recently, we introduced polymer-based metal ion aﬃnity
capture (PolyMAC), a soluble reagent based on a titanium(IV)functionalized PAMAM dendrimer, which demonstrated
enhanced reproducibility and selectivity.26 Other studies have
shown the eﬀectiveness of using both Zr- and Ti-based reagents
for phosphopeptide enrichment, as well as the ability of each to
capture a unique set of phosphopeptides.27 Therefore, to
complement our titanium-bound nanopolymer, we developed
PolyMAC-Zr, a zirconium(IV)-functionalized PAMAM G4
dendrimer. Here, we present PolyMAC-Zr as a novel reagent
for phosphopeptide enrichment and utilize the complementary
PolyMAC-Ti and PolyMAC-Zr enrichment methods to
examine the role of Syk-dependent phosphorylation in BCR
signaling. Quantitative phosphoproteomics based on stable
isotope labeling via amino acid in culture (SILAC)28 was
employed to identify downstream eﬀectors of Syk. Using the
Syk substrate-site inhibitor piceatannol7 and comprehensive
sample fractionation with reversed-phase liquid chromatography (RPLC) or hydrophilic interaction chromatography
(HILIC), we were able to quantify close to 5000 sites of
phosphorylation that were signiﬁcantly aﬀected by the activity
of Syk after BCR stimulation from over 16 000 identiﬁed
unique phosphorylation sites. Functional and pathway
annotations conﬁrmed many known functions of Syk, but
also revealed potential novel roles, including a role in
modulating changes in protein ubiquitination.

■

METHODS

Synthesis of PolyMAC-Zr Reagent. Polyamidoamine
dendrimer generation 4 (PAMAM G4) solution (200 μL;
provided as 10% w/v in methanol; Sigma-Aldrich) was dried
and redissolved in 1 mL of dimethyl sulfoxide, then 6 mg of
Boc-aminooxyacetic acid, 15 mg of N-hydroxybenzotriazole
(HOBt), and 10 μL of N,N′-diisopropylcarbodiimide (DIC)
were added and reacted overnight. The mixture was transferred
to a 10 mL round-bottom ﬂask, and an equal volume of 250
mM MES (2-(N-morpholino)ethanesulfonic acid; pH 5.5)
buﬀer was added to it. Next, 16 mg of carboxyethylphosphonic
acid, 16 mg of N-hydroxysuccinimide, and 160 mg EDC (1ethyl-3-(3-(dimethylamino)propyl)carbodiimide hydrochloride) were added to the mixture and stirred overnight. The
solution was dialyzed against water, reacted with 0.1 M ZrOCl2
for 90 min, and evaporated to complete dryness. The solid was
redissolved in 80% triﬂuoroacetic acid and reacted for 90 min.
The mixture was dialyzed successively against a 1:4 DMSO/
water mixture and water. The ﬁnal PolyMAC-Zr product was
stored at 4 °C.
Phosphopeptide Enrichment. Preparation of phosphopeptide samples from DG-75 B cells and PolyMAC-Ti
enrichment were carried out in a similar fashion, as described
before.26 For PolyMAC-Zr, the peptide mixture was dissolved
in 100 μL of the loading buﬀer (200 mM glycolic acid, 1%
triﬂuoroacetic acid, and 50% acetonitrile); 5 nmol of PolyMAC6364
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capable of eﬀectively binding to phosphate groups, and this
property has been successfully explored for both phosphopeptide enrichment19,29 and DNA capturing30,31 using solid
supports. To further explore the utilization of zirconium ion
for phosphopeptide enrichment, we developed a soluble
nanopolymer-based reagent, PolyMAC-Zr (Figure 1a), poly-

formic acid in ultrapure water with an elution buﬀer of 0.1%
formic acid in 100% CH3CN run over a shallow linear gradient
(from 2% CH3CN to 35% CH3CN) over 90 min with a ﬂow
rate of 300 nL/min. The electrospray ionization emitter tip was
generated on the packed column with a laser puller (model P2000, Sutter Instrument Co.). The Eksigent Ultra 2D HPLC
system was coupled with a hybrid linear ion trap Orbitrap mass
spectrometer (LTQ-Orbitrap Velos; Thermo Fisher). The mass
spectrometer was operated in the data-dependent mode in
which a full scan MS (from m/z 300 to 1700 with a resolution
of 30 000 at m/z 400) was followed by 20 MS/MS scans (for
SILAC samples, 7 MS/MS scans were used) of the most
abundant ions. Ions with a charge state of +1 or undetermined
charge states were excluded. The mass exclusion time was 90 s.
Database Search. The LTQ-Orbitrap raw ﬁles were
searched directly against a human database using SEQUEST
or MASCOT on Proteome Discoverer (version 1.3, Thermo
Fisher). Proteome Discoverer created DTA ﬁles from raw data
ﬁles with minimum ion threshold 15 and absolute intensity
threshold 50. The peptide precursor mass tolerance was set to
10 ppm, and the MS/MS tolerance was set to 0.8 Da. Search
criteria included a static modiﬁcation of cysteine residues of
+57.0214 Da and a variable modiﬁcation of +15.9949 Da to
include potential oxidation of methionine and a modiﬁcation of
+79.996 Da on serine, threonine, or tyrosine for the
identiﬁcation of phosphorylation. Searches were performed
with full tryptic digestion and allowed a maximum of two
missed cleavages on the peptides analyzed from the sequence
database. False discovery rates (FDR) were set to 1% for each
analysis. The number of unique phosphopeptides and nonphosphopeptides identiﬁed were then counted using an inhouse software. Phosphorylation site localization from CID
spectra was determined by PhosphoRS on Proteome
Discoverer 1.3. For SILAC experiments, in addition to the
above parameters, a dynamic modiﬁcation of +6.020 Da was
added on arginine and lysine. The quantiﬁcation method was
set to SILAC 2plex (Arg6, Lys6) and light/heavy ratios were
reported.
Data Analysis. Unique peptides were extracted on the basis
of the m/z value and the charge state using an in-house
software. The actual phosphorylation sites were determined by
the PhosphoRS score, and only the top scoring phosphorylation site was reported for any phosphopeptide with
potentially ambiguous sites. Following the standard SILAC
quantiﬁcation approach,10 the cutoﬀ values for phosphorylation
changes were determined and above or below 2-times the
standard deviation from the mean was considered as a
signiﬁcant change. To predict upstream kinases for identiﬁed
phosphosites, in-house software utilizing the kinase motifs
listed on human protein reference database was used.
Pathway Analysis. A list of proteins was extracted
corresponding to the peptides selected above. This list with
decreased and increased phosphorylation and the corresponding SILAC ratios were submitted to Ingenuity Pathway Analysis
(IPA) (Ingenuity Systems). The IPA criteria were set to include
only known human cellular proteins and their direct
interactions. In addition, protein functions were predicted
using DAVID bioinformatics tool.

Figure 1. Basic structure and functional evaluation of PolyMAC-Zr.
The structure of PolyMAC reagent and the structural diﬀerences
between PolyMAC-Zr and PolyMAC-Ti. (a) Evaluation of PolyMACZr using DG75 cell lysates. (b) Comparison of three PolyMAC-Zr
phosphopeptide enrichment experiments showing the number of
phosphopeptides (blue) enriched in each experiment and the number
of nonphosphopeptides (red) identiﬁed in each experiment. (c)
Comparison of PolyMAC-Zr and PolyMAC-Ti for the number of
phosphopeptides enriched and the selectivity (average of 3 replicates,
phosphopeptides in blue, nonphosphopeptides in red). (d)
Phosphopeptide identiﬁcation overlap of phosphopeptide enrichment
between any two PolyMAC-Zr experiments or PolyMAC-Zr and
PolyMAC-Ti experiments (3 replicates).

amidoamine (PAMAM) generation 4 dendrimer functionalized
with Zr4+ ions. Hydroxylamine groups were attached to the
dendrimer, which were used as the “handle” to capture the
dendrimer onto aldehyde-functionalized agarose beads through
a rapid covalent reaction. During phosphopeptide enrichment,
a complex peptide mixture is incubated with the PolyMAC-Zr
reagent in solution, resulting in the rapid and selective binding
of phosphopeptides in the homogeneous solution. The
phophopeptide-bound PolyMAC-Zr reagent is then isolated
using the aldehyde-functionalized beads. Last, the bound

■

RESULTS AND DISCUSSION
PolyMAC-Zr for Phosphopeptide Enrichment. We
introduced recently PolyMAC-Ti for eﬃcient capturing of
phosphopeptides.26 In addition to titanium, zirconium is
6365
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phosphopeptides are eluted under basic conditions for mass
spectrometric analysis. The capability of the reagent to
eﬀectively enrich phosphopeptides was ﬁrst evaluated using a
simple mixture containing angiotensin II and phosphorylated
angiotensin II (Supporting Information (SI) Figure S1) and
then with a panel of peptides generated from phosphorylated
(α-casein, β-casein, and ovalbumin) and unphosphorylated
proteins (lactalbumin, β-lactoglobulin, catalase, hemoglobin,
and bovine serum albumin). Before enrichment, the majority of
peaks detected by MALDI-TOF analysis were nonphosphopeptides. After the enrichment, only phosphopeptides were
observed (SI Figure S2).
To evaluate the performance of the new reagent for use in a
complex mixture, we further tested it with a whole-cell lysate
generated from the human Burkitt’s lymphoma B cell line,
DG75. A 100 μg sample of the cell lysate was digested with
trypsin and subjected to phosphopeptide enrichment by
PolyMAC-Zr. Among the various tested loading buﬀer
conditions, a solution consisting of 200 mM glycolic acid,
50% acetonitrile, and 1% triﬂuoroacetic acid was optimal for
high selectivity and recovery (data not shown). The PolyMACZr reagent captured over 1200 unique phosphopeptides from
100 μg of DG75 cell lysate with over 60% selectivity for
phosphorylated peptides (Figure 1b,c). The overlap of
identiﬁed phosphopeptides between any two experiments was
∼75%, demonstrating the excellent reproducibility of homogeneous capture with PolyMAC-Zr (Figure 1d), consistent with
previous studies with PolyMAC-Ti.26 On the other hand, the
overlap of phosphopeptides enriched by PolyMAC-Zr and
PolyMAC-Ti was <50% (Figure 1d), indicating each metal ion
enriched a unique set of phosphopeptides.
In-Depth Analyses of Syk-Dependent Phosphorylation in B Cells. PolyMAC-Zr was used in combination with
PolyMAC-Ti to investigate Syk-dependent phosphorylation in
B cells following anti-IgM stimulation of the BCR. Two
populations of DG75 cells were grown in SILAC media
containing either “light” or “heavy” (13C6-labeled) arginine and
lysine. One group of cells was treated with the Syk inhibitor,
piceatannol, and the other group was treated with DMSO as a
control. Both sets were stimulated with anti-IgM antibody to
activate the BCR signaling pathway. Equal amounts of protein
(2.5 mg) extracted from each cell population were mixed and
digested with trypsin.
To reduce the sample complexity, we used RPLC32 or
HILIC25 in the ﬁrst dimension of peptide fractionation. HILIC
and RPLC are complementary separation methods,25,33 and we
used PolyMAC-Zr to enrich phosphopeptides after HILIC
fractions. The orthogonality of RPLC was achieved by
separating peptides at high (pH 8) and low pH (pH 2.6)
values in the two dimensions.32,34 Previously, this has been
successfully applied for both phosphopeptide and nonphosphopeptide separations.32,34,35 Each RPLC fraction was
enriched for phosphopeptides using PolyMAC-Zr or PolyMAC-Ti before the LC−MS/MS analysis. Figure 2 summarizes
the total number of phosphopeptides, the number of unique
phosphopeptides obtained from each fractionation approach,
and the distribution of phosphopeptides in diﬀerent fractions.
As expected, the unique phosphopeptides identiﬁed using
PolyMAC-Zr versus PolyMAC-Ti demonstrated only about
50% overlap. A total of 13 029 unique phosphopeptides
representing over 16 000 unique phosphorylation sites were
identiﬁed in this study. The distribution of serine, threonine,
and tyrosine phosphosites is illustrated in Figure 2c. The

Figure 2. Summary of B cell phosphopeptide fractionation and
enrichment. (a) The number of phosphopeptides identiﬁed in each
fraction in three separation and enrichment combinations. RPLC and
HILIC fractions enriched by PolyMAC-Zr and RPLC fractions
enriched by PolyMAC-Ti. (b) Upper panel shows the phosphopeptide
overlap of RPLC fractions enriched with PolyMAC-Ti and PolyMACZr. Lower panel shows the overlap between RPLC and HILIC
fractions both enriched with PolyMAC-Zr. (c) The pie chart shows the
percentages of serine, threonine, and tyrosine phosphorylation sites
identiﬁed in the study.

relative abundances of 0.05%, 10%, and 90% have been
reported for phosphotyrosine, phosphothreonine, and phosphoserine, respectively. Here, we identiﬁed 437 (2.6%)
phosphotyrosine, 2447 (15.1%) phosphothreonine, and
13304 (82.2%) phosphoserine sites. The relative abundances
are close to expected values for phosphothreonine and
phosphoserine but signiﬁcantly higher for phosphotyrosine.
Such diﬀerences have been reported in previous studies that
utilized extensive fractionation to enable identiﬁcation of lowabundance proteins that are usually phosphorylated on tyrosine
residues.10 We compared quantitatively the “light” to “heavy”
ratios of identiﬁed phosphopeptides between the piceatannoltreated and untreated samples to assess the importance of Syk
to BCR-stimulated phosphorylation. Out of 13 029 unique
6366
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Figure 3. Regulation of cellular functions by Syk dependent phosphorylation. (a) Distribution of consensus kinase motifs within the data set. (b) A
summary of B cell functions perturbed by Syk inhibition.

phosphopeptides, 1506 showed more than a 2-fold increase,
whereas 2340 showed more than a 2-fold decrease after
treatment with the inhibitor. These unique phosphopeptides
provided a list of 1982 phosphorylation sites with increased
phosphorylation from 1049 proteins and 2960 sites with
decreased phosphorylation levels from 1446 proteins (SI
Tables S1 and S2).
Regulation of Cellular Functions by Syk-Dependent
Phosphorylation. In the presence of an antigen, B cell
receptor (BCR) aggregates and transduces signals to the cell
interior by activating Src-family kinases Lyn, Blk, and Fyn, as
well as tyrosine kinases Syk and BTK. These participate in
signaling complexes that include adaptor proteins, such as
CD19 and BLNK, and signaling eﬀectors, such as PLCγ, PI3K,
and VAV. Signals transduced through these components
activate multiple downstream signaling cascades, inducing
changes in cellular metabolism, gene expression, and
cytoskeletal organization. These signaling cascades can regulate
survival, tolerance, proliferation, or diﬀerentiation of B
cells.2,36,37 Therefore, it is important to understand the Sykdependent processes of these complicated signaling events.
Elucidation of these processes can be facilitated by examining
signaling events with and without the inhibition of Syk using
piceatannol. Proteins directly involved in these pathways
typically demonstrate decreased levels of phosphorylation
upon Syk inhibition. However, feedback loops and lack of
activation of phosphatases may result in increased levels of
phosphorylation in some proteins.36−38

To further understand the Syk-dependent changes in
phosphorylation, the nature of upstream kinases were predicted
on the basis of the sequences of phosphorylation sites using
software developed in-house, as shown in Figure 3a. A list of
kinase motifs was extracted from the human protein reference
database (HPRD),39 and upstream kinases were predicted for
all the phosphorylation sites identiﬁed with changing
phosphorylation levels. The normalized fraction of phosphorylation sites for each kinase is illustrated in Figure 3a, where a
positive value indicates the fraction of phosphorylation sites
with increased phosphorylation and a negative value indicates
the fraction of phosphorylation sites with decreased phosphorylation upon treatment with piceatannol. According to the
above analysis, calmodulin-dependent kinase motifs are found
only among the sites with decreased phosphorylation. Intracellular calcium levels increase during BCR signaling1 and Syk
inhibition interrupts proper signal propagation,40 which may
lead to the decreased activity of calcium-dependent kinases.
AKT and NIMA kinase motifs are represented only among sites
with increased phosphorylation. AKT is activated downstream
of BCR engagement in B cells; therefore, a decrease in AKT
activity is expected upon Syk inhibition. However, this observed
increase in phosphorylation could be due to the fact that most
cultured lymphoid cell lines, including DG75, lack both PTEN
and SHIP1 and have constitutively active AKT. 41−43
Furthermore, there are signiﬁcantly higher numbers of CDClike kinase 1 (CLK1) and AMP-activated protein kinase
(AMPK) sites with decreased phosphorylation. AMPK is
6367
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Figure 4. (a) Phosphorylation on ubiquitin proteasome pathway proteins. The plot indicates the SILAC fold changes (x axis) of E1, E2, E3 ligases,
deubiquitinases, and proteasome components. Positive and negative values represent phosphorylation increase and decrease, respectively. Western
blots indicating Syk dependent ubiquitination. (b) Anti-ubiquitin Western Blot of proteins from DG75 B cells treated without (−) or with (+)
piceatannol. GAPDH was used as the loading control.

Furthermore, the substrate speciﬁcities of many kinases overlap,
making it diﬃcult to attribute speciﬁc phosphorylation events
to a single kinase. Still, some of the kinase motifs show
signiﬁcant enrichment among groups of sites with distinctive
higher or lower phosphorylation levels. On the other hand,
functional annotation provides complementary information
that can be correlated with phosphorylation changes of kinase
speciﬁc sites. For example, we have identiﬁed NPM1, NUDC,
and BUB1B which are PLK1 substrates during centrosome
organization. Therefore, it is likely that these kinases are acting
as nodes in various downstream pathways that are modulated
by Syk in B cells. Some of the important pathways and
functions are summarized in Figure 3b, and the protein lists are
given in the SI Tables S3−5. The function of Syk in the
immune system has been widely studied,52 and we observed the
B cell receptor (BCR) signaling pathway as the most perturbed
canonical pathway (SI Figure S5). Furthermore, other known
Syk-dependent networks, such as FcγRIIB, PI3K, PLC
signaling, NFAT regulation,2 and centrosome organization,
were also observed. More interestingly, we identiﬁed RNA post
transcriptional modiﬁcation and the ubiquitin proteasome
pathway as novel potential Syk-dependent pathways.
Syk-Dependent Ubiquitination in B Cells. One of the
most intriguing networks in our data annotation is the ubiquitin
proteasome pathway (SI Figure S6 and Table S5). We
identiﬁed and quantiﬁed a signiﬁcant number of phosphorylated nodes that function in this pathway, including E1, E2, E3
ligases, proteasome components, and deubiquitinases (DUBs).
The proteins belonging to the above categories are summarized
in Figure 4a with the SILAC fold change ratios obtained for
identiﬁed peptides. Among the diﬀerent classes of proteins in
the ubiquitin proteasome pathway identiﬁed in this study,
DUBs are the most prominent group. The majority of DUBs
were found to contain signiﬁcantly decreased levels of

known to be activated downstream of the T cell receptor
(TCR) in a manner dependent on CaMKKs and the Zap-70
substrates LAT and SLP76.44 CLK1 is a dual speciﬁcity kinase
expressed in the nucleus that is involved in mRNA splicing.45
Serine/arginine rich proteins are known substrates for this
kinase,46 and several such proteins show decreased phosphorylation levels in our study. Interestingly, we identiﬁed RNA
post-transcriptional modiﬁcations pathway as one of the
perturbed networks upon Syk inhibition (Figure 3b, SI Figure
S3 and Table S3). Speciﬁcally, mRNA spicing factors,
ribonuclear proteins and splicing regulatory proteins show
signiﬁcant changes in levels of phosphorylation.
Interestingly, Src-family kinases, polo-like kinase 1(PLK1),
and ataxia telangiectasia mutated kinase (ATM) substrate sites
are enriched among sites with increased phosphorylation. Syk
and Src family kinases are known to participate in signaling
cross-talk47 and may have nonredundant48 or opposing49 roles
in some pathways. Therefore, Syk inhibition may have aﬀected
cross talk between Syk and Src kinases, resulting in increased
levels of Src family kinase-dependent phosphorylation. PLK1,
on the other hand, functions in centrosome maturation, spindle
assembly and cytokinesis. Prior experiments have revealed
autophosphorylation-dependent centrosomal localization of
Syk4,6,50 and colocalization of Syk and PLK1 at mitotic spindle
poles.51 Threonine phosphorylation on Syk by PLK1 has been
reported to be a part of an antiapoptotic mechanism, and the
disruption of the mechanism may have activated alternative
PLK1-dependent phosphorylation events.51 Furthermore, we
have identiﬁed centrosome organization as one of the functions
perturbed upon Syk inhibition (Figure 3b, SI Figure S4 and
Table S4)
A limitation in upstream kinase prediction is the lack of
known consensus sequences for the majority of kinases, and
therefore the study was restricted to a few kinases.
6368
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Figure 5. Network analysis of proteins with decreased ubiquitination. (a) RNA posttranscriptional modiﬁcation network. (b) Nucleotide metabolism
network: enzymes (blue), transcription regulators (green), peptidases (pink), transporters (purple), kinases (yellow), and other proteins (orange).
Protein names are given in the list of abbreviations in the Supporting Information.

nucleic acid metabolism are prominent among proteins with
decreased ubiquitination, illustrated in Figures 5a and 5b,
respectively. For example, Pre-mRNA-processing-splicing factor
8 (PRPF8), heterogeneous nuclear ribonucleoprotein H3
(HNRNPH3), RNA-binding protein 39 (RBM39), and U2
small nuclear ribonucleoprotein B (SNRPB2) are among
proteins functioning in RNA posttranscriptional regulation
speciﬁcally by RNA processing and splicing with decreased
ubiquitination levels upon Syk inhibition.

phosphorylation on one or more sites after Syk inhibition, such
as Y364 on ubiquitin speciﬁc peptidase 10 (USP10).
Deubiquitinases are tightly regulated both spatially and
temporally, similar to ubiquitin ligases, thus enabling careful
control over cellular signaling and protein stability.53
Phosphorylation is thought to be a key regulatory mechanism
for DUBs, as was demonstrated by a recent study of the human
deubiquitinase DUBA being controlled through phosphorylation at S177 by casein kinase (CK2),54 and USP25 has been
reported as a Syk substrate.55 This is the ﬁrst report on the
regulation of ubiquitination by Syk.
Proteomics Analysis of Syk-Dependent Ubiquitination. To identify ubiquitinated proteins modulated by Syk,
DG75 cells were treated with MG132 to inhibit the
proteasome, and half of the cells were also treated with
piceatannol to inhibit the Syk activity. An examination of global
protein ubiquitination by Western blot analysis showed a
substantial decrease in protein ubiquitination following the
treatment of cells with piceatannol (Figure 4b). After cell lysis
and protein digestion, the ubiquitinated peptides were enriched
using an antibody raised against the diglycine motif, and the
resulting peptides were identiﬁed using LC−MS/MS. Quantiﬁcation was achieved in a label-free manner using a synthetic
peptide library.56 This examination resulted in the identiﬁcation
and quantiﬁcation of over 1300 unique ubiquitination sites.
Although the overall level of ubiquitination was increased, after
setting the cutoﬀ values at 2-fold changes based on the library
peptide normalization, we found that 360 and 520 peptides
showed decreased and increased ubiquitination representing
282 and 372 proteins, respectively (SI Table S6,7). It should be
noted that antiubiquitin antibody used for Western blots shows
stronger signals for polyubiquitinated proteins, whereas antibody against diglycine residue does not distinguish between
mono- and polyubiquitination. Hence, the ubiquitin proteomics
experiment may not perfectly match the Western blot results.
Our goal was to speciﬁcally identify proteins with decreased
ubiquitination upon Syk inhibition. A functional annotation was
carried out for the proteins with increased or decreased
ubiquitination. IPA analyses revealed that the proteins with
functions in RNA post transcriptional modiﬁcations, and

■

CONCLUSION

■

ASSOCIATED CONTENT

Previous studies on Syk-dependent signaling events in B cells
focused mainly on tyrosine phosphorylation, thus limiting
information on potentially diverse Syk functions and downstream signaling events. Because Syk is an upstream kinase
within several signaling cascades, there are numerous
opportunities for serine/threonine phosphorylation events
that can be modulated by its kinase activity. Our integrated
approach of using complementary Ti- and Zr-based phosphopeptide enrichment with RPLC and HILIC fractionation has
led to identiﬁcation of over 16 000 unique phosphorylation
sites and quantiﬁcation of nearly 4000 peptides with signiﬁcant
phosphorylation changes. The annotation of corresponding
proteins reiterated known Syk-dependent functions and
suggested novel potential networks. Furthermore, canonical
pathway analysis suggested a signiﬁcant inﬂuence of Syk activity
on ubiquitination network in B cells. The subsequent
examination of the dependence of ubiquitination on Syk
activity was carried out, and among more than 1300
ubiquitination sites identiﬁed, the data showed decreased
ubiquitination levels in RNA processing and splicing proteins
in response to Syk inhibition.

* Supporting Information
S

Additional information as noted in text. This material is
available free of charge via the Internet http://pubs.acs.org.
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